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Type 2 diabetes (T2D) is a highly prevalent complex disease characterized by 
defective insulin secretion in the pancreatic p cells and insulin resistance in the liver, 
muscle and adipose tissues, but their pathogenic mechanisms are not fully understood. 
This study hypothesized that common polymorphisms in the genes encoding 
nutrients-, glucose-, and insulin-responsive transcriptions factors and their 
downstream targets may be implicated in these pathways and influence susceptibility 
to T2D. 
Eight candidate genes from the insulin secretion pathway {HNF4A, HNFIA, 
PDXl, PBXl, NEURODl, GCK, KCNJll and ABCC8) and six candidate genes from 
the insulin action pathway {PPARG, PPARA, PPARGCIA, ADIPOO, LPL and UPC) 
were selected respectively. A two-stage case-control association study in 1462 T2D 
cases and 600 controls from the Hong Kong Chinese population was conducted. The 
first stage investigated 152 SNPs in 467 T2D cases with early onset familial diabetes 
and 290 controls. The second stage followed up 22 nominally significant SNPs in 994 
random T2D cases and 310 controls. The association between genetic polymorphisms 
i 
and T2D, T2D-subtypes and metabolic trait, as well as gene-gene interactions and 
additive effects were explored. 
The key findings of this study included 1) polymorphisms in HNF4A, 
ADIPOQ, LPL and PPARA were associated with T2D susceptibility; 2) different 
forms of diabetes were attributed by genes from different pathways. Genes implicated 
primarily in insulin secretion (e.g. HNF4A) lead to early onset T2D, whereas genes 
implicated in insulin action pathway (e.g ADIPOQ) conferred risk for T2D later in life 
with coexistence of metabolic syndrome; 3) these genes likely regulate both glucose 
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CHAPTER 1. Introduction 
1.1. Epidemiology of Type 2 Diabetes 
Diabetes is one of the most prevalent complex diseases in the world. Over 
150 million individuals are affected globally, and another 150 million are estimated to 
remain undiagnosed (Zimmet et al 2001; Diamond 2003). The number of diabetic 
patients is projected to increase to 366 million in 2030 (Wild et al. 2004). While type 
1 diabetes (TID) is relatively rare, type 2 diabetes (T2D) is the predominant form 
accounting for more than 90% of all forms of diabetes. T2D represents a cluster of 
metabolic diseases characterized by elevated glucose level, and its development is 
subjected to genetic and environmental factors. Epidemiological studies revealed that 
T2D is more prevalent in populations that adopt an affluent lifestyle such as Mauritius, 
Singapore and Taiwan (13%, 12% and 9%) compared to less affluent areas such as 
rural China (< 5%) (Zimmet et al. 2001; Diamond 2003). Faced with the increasingly 
westernized lifestyle in developing countries such as China and India, the World 
Health Organization (WHO) predicted that one-third of the world's diabetics will be 
Asians by year 2030 (Wild et al. 2004). Poorly controlled diabetes is associated with 
various complications such as retinopathy, nephropathy, neuropathy, cardiovascular 
diseases and stroke (Meetoo et al. 2007), and treatments of these diseases pose major 
therapeutic challenges. In addition to deteriorating the quality of life in the diabetic 
patients, these diseases also strain the public health care system by accounting for 
15% of annual health care costs in the US (Zimmet et al. 2001; Diamond 2003). In 
light of the enormous medical, social and economic burden that T2D imposes on the 
world especially in Asia, a better understanding of its pathogenesis is important for 
controlling this disease. 
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Figure 1.1: Estimated increasing prevalence of diabetes from 2003 to 2025. Adopted 
from International Diabetes Federation, 2003 (International Diabetes Federation 2003) 
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1.2. Risk factors contributing to Type 2 Diabetes 
1.2.1. Environmental and physiological factors 
Several risk factors including high fat diet, physical inactivity, general and 
central obesity, increasing age, smoking, family history of diabetes and history of 
gestational diabetes are implicated in the development of diabetes. The role of 
environmental factors is evidenced by the higher prevalence of diabetes in Asian 
migrants living in US compared to those living in Asia (Fujimoto et al 1994). 
Epidemiological studies indicated that high fat diet is coupled to higher risk of T2D 
(Zimmet et al 2001; Diamond 2003), and lifestyle intervention including healthy diet 
and regular exercise successfully reduced the progression from impaired glucose 
tolerance (IGT) to T2D (Sato et al. 2007). The beneficial role of long term exercise 
has also been shown to ameliorate T2D (Sato et al. 2007). With the socio-economic 
development which led to a more affluent lifestyle, WHO observed a global trend of 
increasingly younger onset of diabetes (King et al. 1998). Moreover, WHO indicated 
a higher prevalence of diabetes in women than in men, raising the possibility that 
gender-specific mechanisms exist (King et al 1998). Conversely, differences in 
diabetes prevalence in different ethnic groups, such as the exceptional high prevalence 
in Pima Indians, is likely due to the interaction of both environmental and genetic 
factors (Savage et al 1979). 
1.2.2. Genetic factors 
The genetic component of T2D is evidenced by family studies. Higher 
concordance rate of diabetes was observed in monozygotic twins (41% to 55%) 
compared to dizygotic twins (10% to 15%) (Harvald et al. 1963; Newman et al 1987). 
3 
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Offspring with both parents affected also had higher prevalence of diabetes (60% at 
60 years old) compared to those with only one parent affected (38% at 80 years old) 
(Pierce et al. 1995; The DECODE study group 1999). Heritability studies also 
demonstrated high heritability {h^ = 0.45-0.63) in diabetes related traits including 
anthropometric indices, blood pressure, lipids, insulin resistance and p-cell function 
(Li et al 2006). 
Depending on the penetrance of the at risk genetic variants, diabetes is divided 
into two forms: monogenic or polygenic. Monogenic diabetes is rare, usually caused 
by single gene mutations with high penetrance. They are characterized by severe 
defects in either insulin secretion (e.g. maturity-onset diabetes of the young (MODY), 
maternally inherited diabetes with deafness, permanent and transient neonatal diabetes) 
or insulin action (e.g. insulin receptor gene mutation and familial lipodystrophy) 
(Owen et al 2007). In contrast, the more common form of T2D is likely caused by 
many common and/or rare genetic variants with modest effects, and additional gene-
gene and gene-environment interactions are often required for the manifestation of the 
disease. Since the presentation of elevated blood glucose resulted from the 
convergence and interaction of diverse primary disturbances (McCarthy et al 2002), 
numerous genetic loci in multiple pathways may be involved. Moreover, these 
genetic variants may exert different effects on different forms of diabetes (e.g. 
diabetes with or without other metabolic risks) or in different populations, and 
interactions with environmental factors may also modify their effects. Thus, T2D may 
be considered as a lifestyle disorder with higher prevalence in populations with 
greater genetic susceptibility (Zimmet et al 2001; Diamond 2003). This complex 
interplay among genetic and environmental factors poses difficulty in studying the 
genetics of T2D. Fortunately, studies in monogenic diabetes had unmasked some 
4 
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critical genes implicated in the impairment of insulin secretion (e.g. GCK, HNF4A, 
HNFIA, TCF2, PDXl, NEURODl, INS, KCNJll, ABCC8, PLAGLl (ZAQ/HYMAl, 
CEL and mitochondria A3243G) and insulin sensitivity (e.g. INSR, LMNA, LMNB2, 
PPARG, AKT2, AGPAT2 and BSCL2) in the pathogenesis of diabetes (Owen et al 
2007). This leads to the hypothesis that at least two distinct groups of genes from the 
two respective pathways may be implicated in the development of the more common 
form of T2D. 
Pmlominantiy insuim dejidem monogenic T2DS f 
Muialions in H N F - I c l HNF-4a . HNF-I|J. IPF. N E U R O D - I , 
jTiiUKhondrial DMA, insulin g e n e s 
1 T 
^ ^ ^ ^ ^ — — X 
ItaipMrinncat tn insuliBt secretion^  \ 
一 _~fPa^St ic J 
— - - — ： ‘ 
"Nj in inxullii s«tisi1ivity 
i i 
Pmhmimuuiy in‘�t“i" resistant ntono^enk- T2DM 
Mulatioiis I'll insulin receptor, PPAR-jr, A K T - 2 genes 
Figure 1.2: Two pathways implicated in the pathogenesis of T2D. Adopted from 
Malecki, 2005 (Malecki 2005) 
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1.3. Disruption of energy homeostasis in the pathogenesis of type 2 diabetes 
1.3.1. Clinical spectrum of type 2 diabetes 
Unlike those of monogenic diabetes, patients with T2D often display defects 
in both insulin secretion and sensitivity at varying degrees. The large number of 
possible interactions between the environmental and genetic factors underlies this 
wide pathophysiological spectrum. Insulin resistance (IR) often precedes IGT and 
overt T2D by many years (Kahn 1994). However, only in the presence of pancreatic 
p-cell dysfunction will IR triggers the progression from normal glucose tolerance 
(NGT) to IGT to T2D (Weyer et al. 1999). In fact, the conversion from NGT to IGT 
to T2D followed a curvilinear relation between normal P-cell function and insulin 
sensitivity (Bergman 1989) (Figure 1.3). Insulin is a key regulator of plasma glucose 
level, and its secretion from pancreatic p-cell directs glucose uptake in peripheral 
tissues. Insulin resistance occurs when the biological effects of insulin are not 
sufficient for both glucose disposal in skeletal muscle and suppression of endogenous 
glucose production in the liver (Dinneen et al 1992). Normally, when IR is present, 
P cells can compensate for the decreased insulin sensitivity by hyper-secreting insulin 
to maintain NGT status, even though they have moved up along the glucose 
intolerance hyperbola. When individuals fail to compensate for IR by hyper-secretion 
of insulin, insulin secretory deficiency (ID) occurs and they become IGT and later 
T2D. 
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I ^ Insulin resistance with 
\ ^-celI compensation 
\ ‘ Insulin resistance without 
\ p-cel I CO mpensatio n 
I V 
^ ^ T2DM ^ 
Insulin sensitivity 
Figure 1.3: Hyperbolic relation between P-cell function and insulin sensitivity. 
Adopted from Stumvoll et al. (Stumvoll et al. 2005) 
1.3.2. Insulin as a key regulator of energy homeostasis 
Throughout evolutionary history, humans (and mammals in general) 
frequently faced shortage of food. Thus, survival depends on a species' efficiency on 
glucose and fat utilization. Fat contains twice the energy per unit mass of 
carbohydrates, but requires more energy to be metabolized (Rosen et al. 2006). 
Plasma glucose level is maintained between 3.9 and 6.1 mmol/1 for normal function. 
When energy is abundant (i.e. during feeding state), insulin is secreted to promote 
glucose and free fatty acid (FFA) uptake in target tissues. It also prevents liver and 
adipose tissues from releasing stored glucose and FFA. Thus insulin maintains 
energy homeostasis by removing excess fuels from blood and storing them 
appropriately. When energy is deficient (i.e. during fasting state), insulin is not 
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secreted, and liver and adipose tissues maintain homeostasis by circulating glucose 
and FFAs. 
1.3.3. Insulin secretion and glucose metabolism 
Pancreatic p cells release insulin in response to elevated plasma glucose, 
known as glucose stimulated insulin secretion (GSIS). When plasma glucose level is 
high, glucose diffuses into the islet cells through glucose transporter type 2 (GLUT2). 
The glucose influx triggers two reactions: 1) insulin gene expression; 2) insulin 
secretion (Fig 1.4). At the level of gene expression, glucose stimulates transcription 
factors (TFs) such as hepatic nuclear factor 4a (HNF4A), neurogenic differentiation 1 
(NEURODl), and the heterodimers of pre-B-cell leukemia homeobox 1 and 
pancreatic and duodenal homeobox 1 (PBXl/PDXl). These TFs interact to upregulate 
insulin transcription (Wang et al 2005). At the level of insulin secretion, glucose 
stimulates HNF4A, which in turn activates hepatic nuclear factor l a (HNFIA) and 
promotes GLUT2 transcription to uptake more glucose. Glucokinase (GCK) controls 
the first rate-limiting step of glycolysis by activate the phosphorylation of glucose into 
glucose 6-phosphate, followed by mitochondrial oxidative phosphorylation to 
generate ATP. The increased ATP/ADP ratio leads to closure of the ATP-sensitive 
potassium channels (KCNJl 1/ABCC8), followed by depolarization of plasma 
membrane and influx of calcium. This calcium influx then leads to exocytosis of 
insulin from their stored vesicles. 
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Mitochondrial oxidative phosphorylation 
• 1 _ 
KCNJ11/ABCC8 
Ca 2+ in flux 
1 
Insulin is released via exocytosis < 
1 1 1 
liver adipocyte muscle 
t Glucose & FFA storage T Glucose & FFA storage 
i Glucose & FFA output | Glucose & FFA output t Glucose & FFA storage 
Figure 1.4: Glucose stimulated insulin secretion in pancreatic P cells. Blue colored 
genes were genotyped. 
1.3.4. Insulin action and lipid metabolism 
Insulin exerts two major effects in its target tissues: 1) promotes glucose and 
FFA uptake in the liver, muscle, and adipose tissues; 2) prevents glucose and FFA 
output by the liver and adipose tissues (Fig 1.5). The efficiency of insulin action is 
dependent on the tissue's insulin sensitivity. For fuel uptake, insulin binds to 
receptors on the cell surface, activating master transcription factors such as 
peroxisome proliferator-activated receptor y subtype (PPARG) in adipose tissue, a 
subtype (PPARA) in liver, and PPARG coactivator l a (PPARGCl A) in muscle (Kota 
et ai 2005; Handschin et al. 2006). These TFs in turn activate downstream target 
genes to achieve a coordinated response in glucose and lipid metabolisms. For 
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example, they up regulate the expression of glucose transporter type 4 (GLUT4) to 
promote glucose uptake in their respective tissues (Hamm et al. 1999; Michael et al. 
2001; Kota et al. 2005; Armoni et al. 2007). PPARG and PPARA also up regulate 
the expression of lipases such as lipoprotein lipase (LPL) and hepatic lipase (LIPC) in 
adipose tissue and liver respectively, so that ingested triglyceride (Wittrup et al.) can 
be released as FFA into the blood stream and oxidized by other cells (Schoonjans et al. 
1996). In addition, PPARG and PPARA up regulate lipogenic gene expression such 
as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) to convert excess 
glucose and FFA into triglycerides for storage in the adipose tissue and the liver 
(Motojima et al. 1998). Insulin also induces the expression of adiponectin (ADIPOQ) 
to interact with these TFs to promote glucose and FFA oxidation in muscle (Tomas et 
al, 2002; Yamauchi et al. 2002). Conversely, insulin inhibits the break down of 
stored glycogen and TG, forcing the body to metabolize the new substrates. 
Insulin 
^ ^ ^ ^ / 丄 ^ ^ ^ ^ 
' 丨 , I 
adipose 蒙 ij^g^ muscle 
PPARG PPARA PPARGC1A 
I I &ADIP0Q1 
tGLUT4 t«-PL t ACC & FAS f GLLrr4 t LPL t ACC & FAS ^ 1 
I I I &LIPC I t GLUT4 t LPL 
^ ^ t c . ^ i t 1 1 
f Glucose t Hydrolyze I com'ert | Glucose t Hydrol.'ze T Convert 
uptake ingested TG uptake ingestedTG excess T Glucose f Hydrolyze 
I I glucose I I glucose uptake mgestedTG 
上 1 & i \ &FFA I 
intoTG 1 
[Glut^ se t FA oxidation 丨 Glucose 丨 Glucose | fa oxidation 丨 Glucose 丨 Glucose 丨 FAoxkJation 
0加咖n &PFA oxidation ^ oxidation 
如 rage storage 
Figure 1.5: Insulin action on target tissues. Blue colored genes were genotyped. 
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During energy deficient state (in which insulin is absent), liver and adipose 
tissues maintain energy homeostasis by releasing glucose and FFA. In the liver, 
HNF4A and PPARGCIA cooperate to activate gluconeogenic genes such as 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P) to 
generate glucose from carbon precursors (Herzig et al 2001; Yoon et al. 2001). In 
the adipose tissue, hormone sensitive lipase (HSL) releases free FA (FFA) by 
hydrolyzing stored TG. The high energy FFA can act as a substrate as well as a 
signaling molecule, and promotes glycogen and TG degradation which are repressed 
by insulin. FFA can down regulate glucose and fatty acid uptake in muscle (Roden et 
al 1996; Roden et al. 2000). FFA can also up-regulate PPARA and its downstream 
lipases (LIPC and LPL) in liver to generate more FFA rapidly (Jump et al. 2005). 
Thus, FFA has opposite effects to insulin and integrate the regulation of both lipid and 
glucose metabolisms. 
O u t p u t FFA 
—FFA 
O u t p u t FFA 
o 3 m^ 
adipose liver 
• • muscle 
个 T H N F 4 A 8 1 P P A R G C I A | PPARA 
T HSL I I I Glucose I FFA 
i t G 6 P & P E P C K t LPL&LIPC u p t a k e u p t a k e 
t Upofysis of I I 
s tored TG t Gkjconeogenesis t Hydro…sis of s tored TG 
t O u t p u t FFA t o u t p u t glucose t O u t p u t FFA 
Figure 1.6: FFA action on target tissues. Blue colored genes were genotyped. 
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1.3.5. Lipotoxicity and glucotoxicity 
The presence of impaired insulin secretion and action leads to excessive 
accumulation of glucose and FFA in the circulation. While acute increase of glucose 
and FFA enhances GSIS, chronic increase inhibits GSIS (Leahy et al. 1988; Leahy et 
al 1988; Boden et al. 1995; Boden 1997). Given that P cell dysfunction triggers the 
conversion from NGT to IGT to T2D (Weyer et al. 1999)，lipotoxicity and 
glucotoxicity are implicated in the pathogenesis of T2D. The chronic elevation of 
plasma FFA level leads to a phenomenon known as lipotoxicity (Sivitz 2001). In 
insulin target tissues such as the muscle and adipose tissues, FFA lowers GLUT 4 
expression and therefore glucose uptake (Leahy et al. 1988; Leahy et al 1988; Boden 
et al 1995; Boden 1997). In the liver, FFA promotes glucose output during feeding 
state (Leahy et al. 1988; Leahy et al 1988; Boden et al. 1995; Boden 1997). In islets, 
FFA down-regulates insulin transcription-activating TFs such as FOXOl and PDXl 
to impair insulin secretion (Hagman et al 2005). FFA also disrupts the intracellular 
FFA/TG cycle to produce toxic ceramide, which leads to beta cell apoptosis 
(Robertson et al. 2004). Given that lipotoxicity reduces both insulin sensitivity and 
secretion, and its manifestation as obesity and IR often precedes overt T2D (Kahn 
1994), excess FFA plays a role in the development of hyperglycemia. The chronic 
elevation of plasma glucose level leads to glucotoxicity (Sivitz 2001)，which increases 
glucose oxidation in islets and thus increases production of toxic reactive oxygen 
species. This oxidative stress results in cellular damages such as decreased PDXl 
level (Robertson et al 2003)，as well as islet cells apoptosis (Stumvoll et al. 2005). 
Furthermore, excess glucose impairs insulin secretion by up-regulating insulin 
transcription-repressing TFs such as CEBPB (El-Assaad et al. 2003). The adverse 
effects of glucotoxicity highlight the importance of 
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maintaining plasma glucose level within a narrow range. Taken together, lipotoxicity 
and glucotoxicity can aggravate each other through their effects on insulin secretion 
and action, forming a vicious cycle that results in p cell failure and eventually 
development of T2D (Fig 1.7). 
p I I Blood Glucose level I t Blood Fatty Acid level [ ^ 
< < 
o： Chronic exposure to Chronic exposure to g. 
i elevated glucose level elevated FFA level = 
I 1 1 i 
« Increased activity of Decreased MAFA and PDX1 
CEBPB = TCF5 binding to insulin gene 
\ / 
impairs insulin gene expression 
II / � II \ , 
Decreased insulin Decreased insulin mediated Increased glucose 
secretion glucose uptake and FFA output 
in pancreas in liver, adipose and muscle in liver and adipose 
1 1 , 1 1 
Impaired Insulin secretion Insulin resistance 
1 . _ _ 1 
Pancreatic beta cell failure 
Figure 1.7: Effects of glucotoxicity and lipotoxicity on insulin secretion and action 
pathways. 
1.3.6. Role of transcription factors as metabolic switch 
Faced with the dilemma of irregular food supply and continuous energy 
demand, humans have evolved to use insulin to direct efficient usage of energy. 
During feeding state, insulin directs most tissues to use glucose as the primary fuel. 
This preference for glucose ensures that all ingested glucose is either burned or stored. 
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During fasting state, the absence of insulin signals most tissues to use FFA as the 
primary fuel and leave glucose for usage by the brain. Thus, insulin plays an 
important role in inducing or inhibiting a cascade of TFs, which in turn activate 
subsets of different genes, to modulate the switch between glucose and FA 
metabolisms for maintaining energy homeostasis. For example, insulin stimulates 
PPARA, PPARG and PPARGCIA, which up-regulate a set of glycolytic and 
lipogenic genes. In addition, energy substrates such as FFA can bind to TFs such as 
PPARA, PPARG and HNF4A directly, making these TFs cellular nutrient-sensors. 
Moreover, TFs always interact by forming dimers with each other to provide a 
complex regulatory network. The insulin-responsive TFs that switch between glucose 
and FA metabolisms are called 'metabolic switch'. In a way, T2D may be considered 
a 'metabolic inflexible state' which resulted from inefficient fuel usage and storage 
(Storlien et al. 2004). In IGT individuals, their tissues continue to rely on FFA for 
fuels even when glucose is available. In IR individuals, their livers output FFA 
instead of oxidizing glucose during feeding, and muscles do not increase FA 
oxidation during fasting (Kelley et al 1999). In overt T2D individuals, impaired 
insulin secretion and action result in defective fuel uptake and usage. Given the 
critical role of TFs in maintaining energy homeostasis, and the link between T2D and 
metabolic inflexibility, this study hypothesized that genetic variants in the insulin-
responsive transcription factors and their downstream targets may be implicated in the 
pathogenesis of T2D. 
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1.4. Candidate genes implicated in type 2 diabetes susceptibility 
As discussed in section 1.3, several TFs and their downstream targets involved 
ill the insulin secretion and action pathways are implicated in T2D development. In 
this study, 14 well-studied candidate genes, including eight TFs and six of their target 
genes, were examined for association with T2D in a Hong Kong Chinese population. 
For the insulin secretion pathway, genes implicated in MODY and neonatal diabetes 
were selected. MODY is characterized by autosomal dominant inheritance and early 
onset of diabetes before the age of 25. Neonatal diabetes refers to the development of 
diabetes within the first six months of life. Both types of diabetes are caused by single 
gene mutations leading to primarily insulin deficient phenotype. For the insulin action 
pathway, genes implicated in the glucose and lipid metabolisms in the liver, muscle 
and in particular, the adipose tissue, were selected. Recent studies showed that 
adipose tissue plays a key role in regulating energy homeostasis via controlling fat 
mass and releasing cytokines (Rosen et al. 2006). In addition, many of these gene 
products are drug targets including GCK, KCNJl 1/ABCC8 and PPARs. Thus it is 
plausible that common variants in the respective genes may be implicated in the 
common form of T2D. Details of the candidate genes and their association with T2D 
in previous studies are described below in sections 1.4.1 and 1.4.2. 
1.4.1. Candidate genes involved in insulin secretion pathway 
1.4.1.1. HNF4A 
Hepatic nuclear factor 4a gene {HNF4A) encodes a TF that belongs to the 
steroid/thyroid hormone receptor super family (Olefsky 2001). It is expressed in the 
liver, kidney, intestine, pancreatic islets and insulinoma cells (Odom et al 2004). 
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Molecular studies showed that HNF4A exerts its effects through inducing other TFs 
(for example, HNFIA and FOXOIA), which in turn induce the transcription of 
downstream target genes (Thomas et al. 2001). Thus it is considered a master 
regulator in the pancreatic and hepatic transcription programs. During feeding state, it 
activates pancreatic gene expressions to promote GSIS. During fasting state, it 
enhances hepatic glucose and FFA output. HNF4A was the first gene that was 
discovered to cause MODY (MODYl). Heterozygous mutation carriers demonstrated 
defective GSIS as well as lower TG, apoAII, apoCIII and lipoproteins levels (Malecki 
2005). Two SNPs (rs 1884614 and rs2144908) located in the 5，promoter region have 
been associated with T2D in Finnish and Ashkenazi populations (Love-Gregory et al. 
2004; Silander et al 2004). Other SNPs have also been associated with higher lipid 
levels and metabolic syndrome (MetS) risk in Finnish families with familial combined 
hyperlipidemia (Weissglas-Volkov et al. 2006). 
1.4.1.2. HNFIA 
Hepatic nuclear factor lot {HNFIA) is also known as transcription factor 1 
(JCFl). It is expressed in the liver, kidney, intestine and pancreatic islets. It encodes 
a TF that binds with HNF4A to regulate pancreatic and hepatic transcription programs. 
A chromatin immunoprecipitation (ChIP) study revealed that it binds to at least 222 
target genes in the liver and 106 target genes in the islets, with 30% of these target 
genes being common to both tissues (Odom et al 2004), Its functions are similar to 
those of HNF4A. In addition, carriers of this gene mutation (M0DY3) have defective 
GSIS as well as lower apoM level (Malecki 2005). A L27I variant in HNFIA has 
been associated with insulin secretion and insulin sensitivity in Caucasians (Chiu et al. 
2000; Chiu et al 2003). 
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1.4.1.3. PDXl/PBXl 
Pancreatic and duodenal homeobox 1 (PDXl), also known as insulin promoter 
factor 1 {IPFJ), is expressed in duodenum and pancreatic islets. Pre B-cell leukemia 
transcription factor (PBXl) is widely expressed in all tissues, except in cells of the B 
and T lineage. The two TFs form dimers to induce insulin gene transcription and 
regulate normal pancreatic function (Kim et al. 2002). Heterozygous mutations in 
PDXl leads to MODY (M0DY4) while homozygous mutations leads to neonatal 
diabetes and pancreatic agenesis (Stoffers et al 1997). Common variants in PDXl 
and PBXl have also been associated with T2D in African American and Caucasian 
populations (Karim et al. 2005; Wang et al. 2005). 
1.4.1.4. NEURODl 
Neurogenic differentiation factor 1 {NEURODl) is also known as beta cell E-
Box transactivator 2 (BETA2). It is expressed in the brain, intestine, kidney and 
pancreatic islets. This TF binds to the E-box sequence at the insulin promoter region 
and regulates its expression (Naya et al. 1997). In vivo study of mice with 
homozygous gene disruption demonstrated insufficient insulin expression, leading to 
abnormal pancreatic islet morphogenesis and overt T2D (Naya et al. 1997). As the 
M0DY6 gene, mutation carriers showed low serum insulin and C peptide levels 
(Malecki et al 1999). An A45T variant has been associated with early onset T2D in 
Chinese (Liu et al. 2006)，as well as type 1 diabetes in Japanese and Caucasian 
populations (Iwata et al. 1999; Malecki et al 2003). 
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1.4.1.5. GCK 
Glucokinase {GCK), also called hexokinase 4 {HK4), is expressed primarily in 
the liver and pancreatic islets. This enzyme catalyzes a rate limiting step of 
phosphorylation of glucose into glucose-6-phosphate, thus acts as a glucose sensor in 
P cells to commit extracellular glucose into the glycolytic pathway and subsequent 
GSIS (Matschinsky et al 1993). As the M0DY2 gene, carriers with GCK mutations 
demonstrated chronic hyperglycemia due to reduced glucose sensitivity, and those 
with more severe mutations are inflicted with permanent neonatal diabetes (PNDM) 
(Velho et al 1992; Njolstad et al. 2001). A common variant A-30G within the p cell 
promoter region has been associated with reduced p cell function in a Japanese 
American population (Stone et al. 1996). 
1.4.1.6. KCNJ11/ABCC8 
The ATP-sensitive potassium (KATP) channel in the pancreatic P cells is 
formed by two subunits. The potassium inwardly-rectifying channel J l l gene 
(KCNJII) encodes Kir6.2 which forms the pore-forming subunit, whereas the ATP-
binding cassette C8 gene (ABCC8) encodes the sulfonylurea receptor regulatory 
subunit (SURl). The K A T P channel is expressed in the brain, heart, skeletal muscle, 
intestine, kidney and pancreatic islets. During feeding state, Katp channel plays a key 
role in insulin exocytosis by its closure incited by increased intracellular ATP/ADP 
ratios during glucose oxidation (Inagaki et al 1995). The hypoglycemic drug, 
sulfonylurea, improves insulin secretion through activating the closure of the K A T P 
channel. KCNJ11/ABCC8 activating mutations cause PNDM (Gloyn et al 2004) 
while inactivating mutations lead to hyperinsulinemia (Nestorowicz et al. 1997). A 
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E23K variant (rs5219) in KCNJll was reproducibly associated with T2D in both 
candidate gene and genome-wide association studies (GWAS), with the rare KK 
genotype conferring a 14% increased risk for T2D in Europeans (Florez et al, 2004; 
Scott et al. 2007; The Wellcome Trust Case Control Consortium 2007; Zeggini et al. 
2007). 
1.4.2. Candidate genes involved in the insulin action pathway 
1.4.2.1. PPARG 
Peroxisome proliferator-activated receptor y gene {PPARG) encodes a TF that 
belongs to the steroid/thyroid hormone receptor super family (Olefsky 2001). It is 
expressed in the brain, liver, large intestine, skeletal muscle, macrophages, adipocytes 
and pancreatic islets (Elbrecht et al 1996; Fajas et al 1997; Mukherjee et al 1997). 
PPARG is known as a key 'fat regulator' (Picard et al. 2004) by binding to the 
peroxisome proliferator response element (PPRE) of target genes to regulate adipose 
transcription program (Kota et al. 2005). PPARG is sensitive to both insulin and FFA 
and is the target for a class of insulin sensitizer known as thiazolidinediones (TZDs). 
During feeding state, it induces lipogenic and glycolytic genes to promote fuel uptake 
and storage in the adipocytes. During fasting state, it enhances hepatic glucose and 
FA output. Carriers with loss-of-function mutations are inflicted with familial partial 
lipodystrophy type 3 (FPLD3) and are characterized by dominantly inherited IR, T2D, 
hypertension, and partial lipodystrophy (Barroso et al 1999). A P12A variant 
(rs 1801282) was associated with T2D in candidate gene studies and was further 
confirmed in recent GWAS, with the common CC genotype conferring a 14% 
increased risk for T2D in Europeans (Altshuler et al 2000; Scott et al 2007; The 
Wellcome Trust Case Control Consortium 2007; Zeggini et al 2007). 
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1.4.2.2. PPARA 
Peroxisome proliferator-activated receptor a gene {PPARA) encodes a TF that 
belongs to the steroid/thyroid hormone receptor super family (Olefsky 2001). It is 
expressed in the liver, kidney, heart, skeletal muscle and macrophages (Braissant et al 
1996; Auboeuf et al. 1997; Chinetti et al 1998). PPARA is sensitive to both insulin 
and FFA (Djouadi et al. 1998). It modulates insulin action in the liver by binding to 
the PPRE of the respective target genes (Kota et al. 2005). During feeding state, it 
induces lipogenic and glycolytic genes to promote fuel uptake and storage in the liver. 
During fasting state, it enhances hepatic glucose and FFA output (Patsouris et al. 
2004). It is the target of fenofibrate (a class of fibrates) action which controls TG, 
total cholesterol and apoB levels (Tai et al. 2002; Kota et al. 2005). A haplotype has 
been associated with earlier age of onset in T2D (Flavell et al 2005), while a V227A 




Peroxisome proliferator-activated receptor y coactivator l a gene {PPARGCIA) 
encodes a transcriptional coactivator that mediates the tissue-specific effects of other 
TFs. It is expressed in the liver, kidney, heart, skeletal muscle, brain, pancreas and 
brown adipose tissue (Esterbauer et al 1999; Wu et al. 1999; Knutti et al. 2000). 
PPARGCIA does not directly bind to DNA sequences, but facilitates selective 
binding between TFs such as HNF4A, PPARG and PPARA and their target genes so 
that only the correct program is induced for each tissue (Handschin et al. 2006). 
During feeding state, PPARGCIA binds to a TF (MEF2C) to promote FA and glucose 
oxidation in muscle (Michael et al. 2001). During fasting state, PPARGCIA binds to 
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HNF4A to promote glucose output in the liver (Herzig et al 2001; Yoon et al. 2001). 
In subjects with IGT or T2D，lower level of PPARGCIA is associated with reduced 
oxidative phosphorylation in the muscle (Mootha et al 2003; Patti et al. 2003; Ling et 
al. 2004). A S482G polymorphism has been associated with T2D in Caucasian and 
Korean populations (Kunej et al 2004; Kim et al. 2005). 
1.4.2.4. ADIPOQ 
Adipocyte, Clq and collagen domain-containing protein (ADIPOQ), also 
called adipose most abundant gene transcript (APMl), is exclusively expressed in the 
adipose tissue (Scherer et al. 1995). It encodes the protein adiponectin that acts as a 
'starvation signal' to promote fuel oxidation in the peripheral tissues (Powell 2007). 
Adiponectin also acts as an 'insulin-sensitizer', and it amplifies insulin's action by 
stimulating the same target kinase (AMPK) (Berg et al. 2001; Tomas et al. 2002; 
Yamauchi et al. 2002). During feeding state, adiponectin demotes gluconeogenesis in 
the liver, and cooperates with PPARGCIA to promote FA and glucose oxidation in 
the muscle (Berg et al. 2001; Tomas et al. 2002; Yamauchi et al. 2002). Studies in 
Pima Indians suggested that a low adiponectin level was correlated with IR and T2D, 
as well as an independent predictor for prospective development of diabetes (Lindsay 
et al. 2002; Stefan et al. 2002; Williams et al 2004). A T45G polymorphism 
(rs2241766) has been associated with T2D in both Asian and Caucasian populations 
(Menzaghi et al 2002; Li et al. 2007). 
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1.4.2.5. LPL 
Lipoprotein lipase gene {LPL) encodes an enzyme that serves as a 
physiological FFA provider by mediating the rate-limiting step of lipolysis of TG into 
FFA, as well as facilitating lipoprotein uptake (Pappan et al. 2005). It is expressed in 
the heart, muscle, liver, adipose tissue, and pancreatic islets. During feeding state, it 
hydrolyzes ingested TG to promote efficient FFA uptake in adipose tissue. During 
fasting state, it hydrolyzes stored TG to promote FA oxidation in the liver and muscle. 
Carriers with severe LPL mutations demonstrated hypertriglyceridemia (Wilson et al. 
1983), while carriers with milder mutations are inflicted with familial combined 
hyperlipidemia (FCHL) characterized by high TG and low HDL levels (Reymer et al. 
1995). A T495G variant (rs320) has also been associated with TG and HDL levels in 
an early-onset T2D Chinese population (Ma et al. 2003). 
1.4.2.6. UPC 
Hepatic lipase gene {UPC) is exclusively expressed in the liver. It shares high 
sequence homology and possesses similar function as LPL (Cai et al. 1989), LIPC 
metabolizes very-low-density lipoprotein (VLDL) into intermediate- (IDL), low-
(LDL) and high- (HDL) density lipoproteins, respectively (Zambon et al 1998). 
Furthermore, it controls plasma HDL concentration by converting HDL2 into HDL3 
(Santamarina-Fojo et al. 2004). It hydrolyzes ingested TG to promote hepatic FFA 
uptake during feeding state, and hydrolyzes stored TG into FFA during fasting state. 
Carriers with LIPC mutations demonstrated hypercholesterolemia and 
hypertriglyceridemia. A C514T variant (rsl800588) has been associated with 
decreased insulin sensitivity and increased TG level in a non-diabetic Japanese 
population (Yabu et al. 2005). 
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1.5. Hypothesis and objectives of the study 
T2D is a highly prevalent complex disease, but its pathophysiology remains 
obscure. Faced with the rising epidemic of T2D in China, and the ethnic differences 
in environmental factors (e.g. lifestyle), risk factor profiles (body composition and 
insulin secretion/resistance patterns) and genetic backgrounds (linkage disequilibrium 
pattern and risk allele frequencies), a better understanding of its pathogenesis in 
Chinese is merited. 
To unravel the underlying genetic factors, several methods such as linkage in 
affected families and association in case control samples using either candidate gene 
or genome-wide approaches have been adopted. While a genome-wide approach 
allows identification of novel genes, a pathway-based candidate gene study allows 
more in-depth examination of each gene region and the analysis of gene-gene and 
gene-environmental interaction with less compromise on study power. 
With the availability of the international HapMap project, systematic survey 
and selection of a catalog of representative "tag" SNPs for each gene becomes 
feasible. This study capitalized on this development and conducted a pathway-based 
two-stage case-control association in a cohort of 1462 T2D cases and 600 controls 
from the Hong Kong Chinese population. Candidate genes which are TFs and/or 
common targets of these TFs from both insulin secretion and action pathways were 
selected, given their implications in the development of T2D. 
The three objectives of this study are as followed: 
1. To systematically examine common genetic polymorphisms in candidate 
genes with a known role in insulin secretion or action pathways, and assess 
their associations with T2D susceptibility using a two-stage approach. 
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2. To determine whether these genes, which have been previously studied 
predominantly in Caucasian populations, have a major role in determining 
type 2 diabetes susceptibility in the Hong Kong Chinese. 
3. To assess whether these genes have a larger impact in the more homogenous 
subgroups of subjects with and without type 2 diabetes. 
4. To detect possible gene-gene interactions. 
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CHAPTER 2. Materials and Methods 
2.1. Study design 
2.1.1. Two-stage candidate gene association design 
T2D is a complex disease that is often described as a "geneticist's nightmare" 
(Neel 1976). To unravel the genetics of T2D, several methods are currently available. 
While linkage studies in families successfully identified genes for Mendelian diseases 
with high penetrance such as MODY, linkage is sub-optimal for detecting disease loci 
with modest effects for common diseases. Thus far, only WFSl, CAPNIO and 
TCF7L2 were found to affect T2D using this method (Strom et al 1998; Horikawa et 
al 2000; Grant et al. 2006). On the other hand, with the availability of the human 
genome sequence, resequencing is ideal for detecting both rare and common causal 
variants in common diseases. However, this method is expensive and laborious and 
thus prohibits examination of large number of subjects and large genomic regions, 
despite the recent advances in this technology and the lowered cost. Alternatively, the 
availability of SNPs and linkage disequilibrium (LD) information through the 
HapMap project makes case-control association studies to be one of the most popular 
designs due to its relative low cost and ease in genotyping，making large scale studies 
possible. Under the "common disease - common variant" hypothesis, common 
diseases are likely caused by multiple common variants (allele frequency > 5%) with 
modest effects, in addition to their interactions with other genes and environmental 
factors. This hypothesis is validated by recent genome-wide association studies 
(GWAS) which found at least 14 susceptibility genes for T2D. These include 
SLC30A8, HHEX, CDKALl, CDKN2A/B, IGF2BP2, FTO, PPARG, KCNJll, JAZFl, 
CDC123-CAMK1D, TSPAN8-LGR5, THADA, ADAMTS9 and N0TCH2 (Saxena et al 
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2007; Scott et al 2007; Sladek et al 2007; Steinthorsdottir et al. 2007; Zeggini et al. 
2007). Interestingly, many of these genes encode TFs that play important roles in the 
pancreatic P-cell insulin secretion. Due to the large number of SNPs being tested in 
GWAS, thousands of samples are required to justify multiple comparisons while 
maintaining study power, which is beyond the scope of this project. 
Instead, we chose a case-control association design for selected candidate 
genes that encode TFs and their downstream targets from two well studied pathways 
on insulin secretion and action. Several steps were taken to improve the chance of 
detecting association. Firstly, SNPs with previously reported T2D-associations in 
other studies (literature significant SNPs) and tag SNPs were selected to validate 
known candidates as well as search for novel SNPs that are relevant to our Chinese 
population. Secondly, a two-stage design is used. In the stage 1 study, patients with 
early onset of diabetes and positive family history were selected due to their likely 
greater genetic loading for T2D. In the stage 2 study, a larger number of patients 
consisting of both early- and late-onset T2D were selected to improve power. We then 
used replication and overall significance in the combined samples to declare 
significance instead of stringent correction of multiple comparisons due to limited 
sample size. Thirdly, the availability of detailed clinical phenotypes allows subgroup 
and metabolic trait analyses which help to dissect the respective pathway/phenotype 
related to the risk alleles, which otherwise may be masked by the genetic and 
phenotypic heterogeneous nature of T2D. In the combined samples, patients were 
subdivided according to age at diagnosis to examine for possible sharing of risk 
alleles across groups. Similarly, MetS often coexists in patients with insulin resistance 
and different genes may be responsible for different form of diabetes. A slightly 
higher female predominance of diabetes as well as sexual differences in phenotypes 
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(e.g. lipids, body composition) and other risk factors (e.g. smoking) also suggest 
possible gene-gender interaction for T2D. For these reasons, subgroup analyses were 
performed in three conditions including 1) family history; 2) MetS; and 3) gender. 
Lastly, given that the genetic effect of a single variant is likely to be modest, 
additional interaction or joint effect with other genetic variants and environmental 
factors will increase the overall effect on T2D susceptibility. 
2.1.2. Power calculation 
The power to detect an association depends on sample size, effect size, risk 
allele frequency and type I error rate (Fig. 2.1). Using a nominal type I error rate of 
5%, the 800 case-control samples in stage 1 have 80% power to detect odds ratios 
(ORs) between 1.3 and 1.8 at risk allele frequency > 0.05. The respective ORs range 
between 1.25 and 1.6 for the 1300 samples in stage 2, and range between 1.2 and 1.5 
in the 2100 combined samples. The latter OR range is similar to those found in recent 
GWAS for T2D (OR = 1.1 to 1.5). The power calculation was performed using PS 
calculator (Dupont et al. 1990). 
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Figure 2.1: Power calculation under a allelic model at 5% type 1 error rate for 
total sample sizes used in a) stage 1; b) stage 2; and c) combined stages 1 and 2 
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2.2. Study cohort 
2.2.1. Subject recruitment 
All subjects in this study were of southern Han Chinese ancestry residing in 
Hong Kong. A total of 1461 unrelated type 2 diabetic patients and 600 unrelated 
control subjects were studied in two stages. The diabetic patients were selected from 
the Hong Kong Diabetes Registry (Yang et al. 2007) recruited between 1995 and 
2002. This registry has comprehensive documentation of demographics, family and 
medical histories, cardiovascular risk factors and complications of patients attending 
the diabetes clinic at the Prince of Wales Hospital (PWH) using standard 
methodology modified from the Europe DiabCare protocol (Piwernetz et al 1993). 
Patients with classic type 1 diabetes with acute ketotic presentation or continuous 
requirement of insulin within 1 year of diagnosis were excluded in this study. The 
stage 1 cases consisted of 467 T2D patients with age of diagnosis (AAD) < 40 years 
and with positive family history of diabetes in first degree relatives. The stage 2 cases 
were randomly selected irrespective of AAD and family history. Amongst these, 298 
and 696 subjects were diagnosed before and after 40 years old respectively. The 
control subjects consisted of hospital staff and participants of a community-based 
cardiovascular risk screening programme. Participants completed a questionnaire on 
demographics, family and medical histories of cardiovascular risk factors and 
complications, and lifestyle. All control subjects were glucose tolerant with fasting 
plasma glucose (FPG) <6.1 mmol/l. A subset of 435 subjects also underwent 75g oral 
glucose tolerance test (OGTT) and their 2-hour glucose level were < 7.8 mmol/l. 
Stage 1 consisted of 290 controls and stage 2 consisted of 310 controls. Informed 
consent was obtained for each participating subject. This study was approved by the 
Clinical Research Ethics Committee of the Chinese University of Hong Kong. 
2 9 
CHAPTER 2. Materials and Methods 
2.2.2. Clinical and biochemical measurements 
Patients attending the PWH diabetes clinic or control subjects attending the 
Diabetes and Endocrine Centre underwent comprehensive assessment after an 8-hour 
overnight fast. Body weight, height, waist (the minimum circumference between the 
umbilicus and xiphoid process) and hip (the maximum circumference around the 
buttocks and symphysis pubis) circumferences were measured in subjects wearing 
light clothing and no shoes. Body mass index (BMI) was calculated as weight (kg) 
divided by height (m) squared. Waist-to-hip ratio (WHR) was calculated as waist 
circumference (cm) divided by hip circumference (cm). Systolic blood pressure (SBP) 
and diastolic blood pressure (DBF) were measured in triplicates separated by one 
minute interval after at least 5 mins in the sitting position，using a Dinamap automated 
sphygmomanometer (Critikon Inc，CA, USA). Fasting blood samples were taken for 
routine laboratory assays including measurement of FPG，lipids (total cholesterol, 
high-density lipoprotein cholesterol (HDL) and triglycerides (Wittmp et al)), liver 
and renal functions. Low-density lipoprotein cholesterol (LDL) was calculated by the 
Friedewald's equation for TG < 4.5 mmol/1 (Friedewald, Levy et al. 1972), where 
LDL (mmol/1) = TC - HDL — (TG/2.2). 10 ml of whole blood was also collected for 
DNA assay. 
A 75 g OGTT was also performed in 435 control subjects. Three fasting blood 
samples collected at 5 minute intervals were assessed for mean FPG and insulin 
(FINS) levels. Blood samples were also collected at 15, 30, 60 and 120 mins during 
the OGTT for measurement of plasma glucose and insulin. Indices for insulin 
sensitivity (HOMA-IR, ISI) and insulin secretion capacity (H0MA-(3, IDI) were 
calculated as follows (Matthews et al 1985; Matsuda et al. 1999): 
1) Homeostasis model assessment for insulin resistance: 
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HOMA-IR == FINS (mU/l)xFPG (mmol/l)/22.5 
2) Homeostasis model assessment for p cell function: 
HOMA-P = FINS x20/(FPG-3.5) 
3) Insulin sensitivity index (ISI) from OGTT: 
ISI = 10000 / (FPG (mmol/1) x FINS (mU/1) x MGLUOGTT (mmol/1) x 
MINSOGTT (mU/1)), where 
MGLUOGTT = average of OGTT glucose at 0’ 30，60，90 and 120 mins; 
MINSOGTT = average of OGTT insulin at 0，30, 60, 90 and 120 mins 
4) Insulin disposition index from OGTT: 
IDI = (INS30 -FINS) (mU/1)/ (GLU30 — FPG) (mmol/1) x ISI /100, where 
INS30 and GLU30 represent insulin and glucose at OGTT 30 mins 
Plasma glucose (hexokinase method), TC (enzymatic method), TG (enzymatic 
method without glycerol blanking) and HDL (direct method using PEG-modified 
enzymes and dextran sulfate) were measured on a Roche Modular Analytics system 
(Roche Diagnostics GmbH, Mannheim, Germany) using standard reagent kits 
supplied by the manufacturer of the analyzer. The precision was within the 
manufacturer's specifications. Insulin were measured with an enzyme linked 
immunosorbent assay (DAKOCytomation, Cambridgeshire, UK). 
2.2.3. Clinical definitions 
Diabetes was defined according to the World Health Organization (WHO) 
1998 criteria (Alberti et al 1998). Subjects with FPG > 7 mmol/1 and/or 2-hour 
glucose > 11.1 mmol/1 during OGTT were considered diabetic. Metabolic syndrome 
(MetS) was defined according to the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP III) guidelines (NCEPIII 2001). Subjects who have at 
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least three of the following five risk factors were classified as having metabolic 
syndrome: 
1) Hyperglycemia with known diabetes or FPG > 6.1 mmol/1; 
2) Hypertension defined as SBP >130 mmHg and/or DBP > 85 mmHg or taking 
antihypertensive medication; 
3) Hypertriglyceridemia defined as TG > 1.7 mmol/1; 
4) Low HDL-cholesterol defined as HDL <1.0 mmol/1 in men or <1.3 mmol/1 in 
women; 
5) Central obesity defined as waist circumference >90 cm in men or >80 cm in 
women. The definition of central obesity was modified for Asian populations (World 
Health Organization 2000) 
2.3. Genetic study 
2.3.1. Candidate gene selection 
According to the hypothesis, eight genes from the insulin secretion pathway 
{HNF4A, HNFIA, PDXl/PBXl, NEURODl, GCK and KCNJl 1/ABCC8) and six 
genes from the insulin action pathway {PPARG, PPARA, PPARGCIA, ADIPOQ, 
LPL and LIPC) were investigated. 
2.3.2. SNP selection 
Single nucleotide polymorphism (SNP), defined as a nucleotide change at a 
single base, is the most common form of genetic variation in the human genome. 
With the genotyping of more than 1 million SNPs in populations of Europeans, 
Asians (Chinese and Japanese) and Africans, the international haplotype map 
(HapMap) project demonstrated that most SNPs are not independently associated 
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with each other. The non-random association between SNPs is described as linkage 
disequilibrium (LD), and can be quantified as D' or r^. While D' reflects the 
recombination events that shaped the haplotyep block structure during evolution 
(Balding 2006), r^ measures the frequency of the alleles of two SNPs cosegregate 
together on the same haplotype. Within a haplotype block, SNPs in high r^ are 
redundant in information and thus a subset of "tag" SNPs that can uniquely identify 
all the haplotypes is sufficient for association study. 
For tag SNP selection in this study, firstly the Han Chinese (CHB) genotype 
data of each gene, including its 2kb upstream and downstream flanking regions, were 
downloaded from HapMap (http://www.hapmap.org) using the NCBI build 35 
assembly. The large intronic regions in four genes {HNF4A, PBXl, PPARGCIA and 
LIPC) were excluded to lower genotyping cost as they are less likely to harbor 
functional variants. 
Secondly, the HapMap data were uploaded into the Haploview program 
(v.3.32) (Barrett et al 2005). Common SNPs with minor allele frequency (MAF) > 
5% were used for tag SNP selection. Using a pair-wise tagging approach, only one 
tag SNP from a group of correlated SNPs (r^> 0.8) was chosen (de Bakker et al. 
2005). The association between SNPs for each gene was visualized as D' and r^ in 
various shades of red and black, respectively (Table 2.1 and Appendix 1). 
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Table 2.1: A) D' color scheme; B) r^  color scheme in Haploview 
A) B) 
D_ < 1 D ' = 1 r^  = 0 0 < r^  < 1 r^  = 1 
LOD < 2 white blue shades o f 
white black 
grey 
shades o f 
LOD > 2 bright red 
pink/red 
Thirdly, during tag SNP selection, coding SNPs and previously-associated 
SNPs were preferably selected or force included. Coding SNPs are more likely to 
exert a functional effect. In addition, SNPs that showed evidence for T2D associations 
in previous studies warrant further investigation in our Hong Kong Chinese cohort. 
Fourthly, SNPs that may fail in assay design or genotyping were preferably 
excluded as tag SNPs. An in-house bioinformatic program was developed to analyze 
the 50bp DNA amplicon surrounding each test SNP. SNPs that showed one or more 
of the following conditions may be excluded: 1) amplicon with 4 or more repeated 
nucleotides that may lead to non-specific primer binding; b) < 40% or > 60% GC 
content which may cause sub-optimal primer binding and dissociation; and c) 
presence of a secondary SNP within 21 bp of the target SNP that may alter primer 
binding efficiency to amplicons with different alleles. 
Details of the gene and SNP selection are shown in Table 2.2. 
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2.3.3. DNA sample preparation 
10 ml of stored peripheral venous blood was de-thawed and then transferred to 
a 50 ml falcon tube. 15 ml of Ix lysis buffer (lOmM KHCO3, 155mM NH4CI，0.1 
mM EDTA) was added. The mixture was iced for 15 mins, then centrifuged at 3000 
rpm at 4°C for 15 mins. After decanting the supernatant, the cell pellet was re-
suspended in 15 ml of lysis buffer, iced, centrifuged, and decanted as before. 3 ml of 
TE buffer, 600 [xl of 10% SDS and 50 i^l of proteinase K solution were then added to 
the cell pellet. After vigorous shaking, the sample was incubated at 65°C overnight. 
The digested sample was cooled for 15 mins before 1 ml of 6 M NaCl was 
added and mixed. After centrifugation at 3000 rpm at 4°C for 15 mins, the 
supernatant was decanted to a 15 ml falcon tube. 1 ml of TE equilibrated phenol and 
1 ml of chloroform was gently mixed in. Following centrifugation, the upper aqueous 
layer was aspirated to a new tube, and 2 ml chloroform was gently mixed in. The 
centrifugation and aspiration were repeated. Two volumes of ice-cold absolute 
ethanol were added and gently inverted to precipitate the genomic DNA. The 
mixture was iced for 15 mins, centrifuged, and the supernatant was discarded. The 
precipitated DNA pellet was transferred to a 1.5 ml eppendorf tube and washed with 
1 ml 70% ethanol. Centrifugation was repeated, the alcohol was drained off, and the 
DNA pellet was left to air dry for 30 mins. Depending on the size of the pellet, 200-
500 jLil of TE buffer was added to dissolve the DNA. The quality and quantity of 
DNA was checked by optical density (OD) measurement in a spectrometer. One unit 
of OD260 is equivalent to 50^g/ml of DNA. A ratio of 1.8-2.0 for OD260/280 
absorbance was considered as good quality. 
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2.3.4. Genotyping methods 
In this project, two genotyping platforms were employed. Of the 198 selected 
SNPs, 135 SNPs in 11 genes were genotyped using the allele specific melting 
temperature (T„i) shift assay, while 63 SNPs in 3 genes were genotyped using the 
Sequenom i-PLEX gold assay. As the study of the 11 genes was in collaboration with 
Roche Pharmaceuticals, the 135 SNPs were genotyped by a technician and me at 
Roche Pharmaceuticals in New Jersey, USA. Of the remaining 63 SNPs, 28 SNPs in 
PBXl were genotyped by the Genome Research Center in Hong Kong University, and 
35 SNPs in PPARA and PPARGCIA were genotyped by the McGill University and 
Genome Quebec Innovation Centre in Quebec, Canada. 
2.3.4.1. Allele specific Tm shift assay 
This singleplex technology makes use of allele-specific polymerase chain 
reaction (PGR), and relies on the differential melting temperatures between amplified 
products to discriminate between genotypes (Germer et al. 1999). Each allele-
specific primer will only bind to the template containing the respective allele for the 
DNA polymerase to amplify. By designing two allele-specific primers with unequal 
length and GC contents, their respective amplified products will have different Tm. 
The longer the primer length, the more unbalance the GC content, the higher Tm, 
which leads to a higher temperature melting curve. 
Figure 2.2 demonstrated the steps of this assay. Three primers (two allele-
specific forward primers and a common reverse primer) were designed for each SNP. 
An in-house algorithm developed by Roche Pharmaceuticals called Tm Calculator 
was used to calculate the Tm, GC content, and primer length for each SNP (Figure 
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2.2, Panel A). The allele-specific primer that ended with a lower T^ base (A or T) 
would receive a short GC-rich tail of 6 bp, while the other allele-specific primer that 
ended with a higher T^ base (G or C) would receive a long GC-rich tail of 14 bp 
(Wang et al 2005) (Figure 2.2，Panel B). The GC-rich tails maximized the T^ 
difference between the alleles to generate two non-overlapping melting peaks. The 
common reverse primer was placed less than 20 bp downstream from the SNP to 
achieve a good balance between amplification efficiency and allele specificity. 
For the PGR amplification, a master mix consisted of lOmM Tris-HCl, 40 mM 
KCl, 2mM MgCb, 50 ^M each ofdATP, dCTP, dGTP, and dTTP，0.2x SYBR Green, 
0.01% Tween 20，4% DMSO, 2% glycerol, 1.8 U of Stoffel Gold polymerase，and 
sterile water was prepared. Then, 9 ng of genomic DNA and 0.2 |iM each of the 
three SNP-specific primers were added to make up a total reaction volume of 15 |il. 
The PGR was then carried out on an ABI 9700 dual block 3 84-well thermal cyclers 
(Applied Biosystems, Foster City，CA) at the following condition: 95°C for 12 mins 
to heat-activate the Stoffel Gold polymerase, followed by 40 cycles of denaturation 
at 95°C for 20s, annealing at 58°C for 40s and extension at 72°C for 20s. 
Following PGR amplification, the samples were transferred to an ABI PRISM 
7900 HT real-time thermal cycler (Applied Biosystems, Foster City, CA) for melting 
curve analysis. The resulting data were imported to an in-house bioinformatic 
program called GCSNPClust for genotype calling. The rate of product dissociation 
(plotted on the y-axis) was compared to the melting temperature (plotted on the x-
axis) to give the T„i profile. Samples homozygous for allele bound by shorter primer 
showed lower Tm curve whereas samples homozygous for allele bound by longer 
primer showed higher Tm curve. Heterozygous samples showed both Tm curves but 
with lower peak height (Figure 2.2, Panel C). Based on the melting curve patterns, 
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the software identified the amplified allele and clustered the samples by their 
genotypes. A tight cluster indicated a reliable genotype calling. 
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Figure 2.2: Protocol for allele specific Tm shift assay. A) T,n calculator; B) allele 
specific primer design; C) GCSNPClust for genotype calling 
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2.3.4.2. Mass spectrometry assay 
This multiplex technology combines PGR amplification, primer extension 
reaction, and allelic-detection by matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS). The protocol is shown in Figure 2.3. 
Firstly, the target DNA region is amplified by PGR using two common primers (one 
forward and one reverse). The PGR product is then cleaned by shrimp alkaline 
phosphatase (SAP) to remove unincorporated dNTPs. Depending on the allele 
present on the DNA amplicon, a single base is inserted next to the extension primer 
and amplified. This leads to a difference in mass between the amplified products 
carrying different genotypes. These amplified products are then placed in the mass 
spectrometer and separated into molecules by laser radiation. The rate of separation 
(measured as time-of-flight) is proportional to the mass of each nucleotide. For this 
reason, lighter molecules will have faster flight while heavier molecules will have 
slower flight. Genotype could then be called based on the resulting mass spectrum. 
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Ampiificaiim 
lO-mer tag 
v^ forward PGR primer 
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Genomic DNA 4 v 








iPl£X Reaction ^ 
Primer extension into SNP site 
Primer extei^ion into SNP site 
1 r 
Sample conditioning, dispensing, and 
MALDI-TOF MS 
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24-plex speclAjm 
Figure 2.3: Sequenome i PLEX genotyping protocol 
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2.4. Data quality control 
2.4.1. Stage 1 study 
Of the 198 selected SNPs, only 159 SNPs were successfully genotyped (Table 
2.2). Genotype data that did not satisfy the following quality controls (QC) were 
removed: samples with call rate < 80%, SNPs with call rate < 85%, SNPs with MAF 
< 0.01, and SNPs showing departure from Hardy Weinberg Equilibrium (HWE) in 
control subjects (P < 0.01). HWE for each SNP was assessed by a y^ test with one 
degree of freedom (Patti et al). Using these criteria, 3 SNPs (rs3767372, rsl472095, 
rs2970855) failed for call rate QC, 2 SNPs (rs 1800467 and rs7535186) failed for 
MAF QC, and 4 SNPs (rs7649121, rs 1169302, rs 11631482 and rs7171818) failed for 
HWE QC. In total, 7 SNPs were excluded, and 152 SNPs remained for analysis. The 
average SNP call rate was 98%. The concordance rate (6659 of 6668 calls) was 
99.9%. 
2.4.2. Stage 2 study 
The 23 SNPs showing significant association to T2D were all successfully 
genotyped in stage 2. After exclusion of samples with call rate < 80%, one SNP 
(rs 182052) had call rate < 85% and was excluded from further analysis. The 22 
remaining SNPs had MAF > 0.05 and showed no departure from HWE (P > 0.01) in 
both cases and controls. The average SNP call rate was 97%. The concordance rate 
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2.5. Statistical analysis 
All statistical analyses were performed with PLINK (v.0.99, available at 
httD://pngu.mGh.harvard.edii/~piircell/plink) (Purcell et al. 2007), Haploview (v.3.32) 
(Barrett et al. 2005) or SPSS 14.0 for Windows (SPSS Inc.. Chicago, IL，USA). A 
nominal P value < 0.05 (2-tailed) was considered to be statistically significant. 
For descriptive statistics, continuous data were expressed as mean 士 standard 
deviation (SD) or geometric mean (95% confidence interval [CI]), and were logarithm 
transformed if necessary. Categorical data were compared using a y} test. 
2.5.1. Stage 1 analysis 
For disease association analyses, genotype frequencies between T2D cases and 
controls were compared using logistic regression under an additive model. Odds ratio 
(OR) with 95% confidence intervals (CIs) were presented with respect to the minor allele 
in cases. Logistic regression was favored over allelic association for its robustness 
against departures from HWE. We hypothesize that candidate genes from different 
pathways may exert different genetic risks in patients with different phenotypes. Thus we 
divided the T2D cases into two subgroups according to the presence or absence of MetS, 
and then compared to all controls to examine for possible modifier effect of MetS on 
genetic association with T2D. 
2.5.2. Stage 2 analysis 
22 SNPs that showed significant association with T2D and/or MetS subgroups 
were further examined in an independent case-control sample in stage 2 using the same 
statistics as in stage 1. 
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2.5.3. Stagel and 2 combined analysis 
In the combined samples, the increased sample size allowed us to examine the 
phenotype-genotype association in more details without compromising the power. For 
the 22 tested SNPs, the best fit genetic models were tested by comparing the additive, 
dominant and recessive models using logistic regression. Haplotypes with frequencies > 
5% were tested for T2D association using haplotype specific test implemented in 
Haploview. To examine the possible confounding or modifying effects of MetS, age at 
diagnosis and gender, subgroup analyses were tested by logistic regression under an 
additive model. Cases with or without MetS were compared to all controls respectively. 
Similarly, cases with early-onset (age at diagnosis < 40 years) or late onset T2D were 
compared to all controls respectively. For gender effect, cases and controls were divided 
by gender and compared to their corresponding counterparts. 
We further tested for possible interaction and joint effects amongst 5 independent 
SNPs that showed consistent associations in T2D，MetS subgroup and/or age at diagnosis 
subgroup analyses. Each of the possible two SNPs interaction was tested one at a time to 
a logistic model containing the 5 SNPs coded under the additive model. In addition, by 
assuming similar effect size, the joint effects of the 5 SNPs, with or without division into 
insulin secretion or action pathways, were assessed for association with T2D. Each case 
or control subject was counted for the number of risk alleles carried, and then assigned to 
a low risk, medium risk, moderately high risk, or high risk allele group using an arbitrary 
allele number cutoff. Due to the modifying effects of MetS and age at diagnosis, the cases 
were further divided into 4 subgroups: 1) MetS negative and early onset T2D; 2) MetS 
negative and late onset T2D; 3) MetS positive and early onset T2D; 4) MetS positive and 
late onset T2D. The cases were then compared to all controls to examine the interacting 
effect of risk allele and phenotypes on T2D association. 
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We also examined for possible associations between SNPs and metabolic traits in 
the 600 control subjects. Continuous data were logarithm transformed and winsorized if 
necessary. Distributions of metabolic traits were compared for different genotypes under 
an additive model by linear regression with adjustment for age and gender. 
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CHAPTER 3. Results 
3.1. Clinical characteristics of subjects in stages 1 and 2 studies 
The clinical characteristics of the study subjects in stages 1 and 2 were 
summarized in Table 3.1. In total, 1461 T2D cases and 600 controls were studied. The 
cases had worse metabolic profiles compared to controls, as evidenced by their higher 
prevalence of MetS (56.2% vs. 4.2% in cases vs. controls) and other MetS risk factors 
(59.4% vs. 27.6% for hypertension, 43.4% vs. 14.9% for low HDL level, 35.2% vs. 
14.0% for hypertriglyceridemia and 48.2% vs. 14.8 for central obesity). 
In this staged study, 467 cases and 290 controls were studied in stage 1, while 994 
cases and 310 controls were studied in stage 2. As expected from the study design, the 
patients in stage 1 were younger (39.2 士 8.5 vs. 54.8 士 12.8 yrs) and had earlier age at 
diagnosis (31.3 土 6.0 vs. 49.6 士 12.3 yrs) than those in stage 2. However, the stage 1 
cases also had better lipid profiles, blood pressure and lower MetS prevalence (52.1% vs. 
58.1%) than the stage 2 cases. Amongst the controls, the stage 1 subjects had lower 
anthropometric measures, lipid profiles and blood pressure compared to the stage 2 
subjects, possibly due to their younger age (39.4 士 10.6 vs. 42.9 士 10 yrs) and lower 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.2. Case-control associations in stage 1 
3.2.1. Association with T2D 
A total of 152 SNPs were successfully genotyped with good quality in stage 1 
samples consisting of 467 early onset T2D cases with positive family history and 290 
controls. Appendix 2 showed the basic information and HWE statistics of all SNPs. To 
investigate the association between these 152 SNPs and T2D, their genotype frequencies 
were compared between cases and controls under the additive model. The complete 
association results were shown in Figure 1 and Appendix 3. Table 1 summarized the 12 
SNPs (7.9%) in 8 genes that demonstrated nominal significant (P < 0.05) association with 
T2D. 
Amongst the 12 SNPs, ADIPOQ, KCNJll and HNF4A showed multiple 
associated SNPs (0.006 <P< 0.025). In ADIPOQ, rs2241766 coding for a synonymous 
change (G15G) had an odds ratio (OR) of 0.76 (P = 0.011) for the protective G allele. 
Another SNP (rsl063539) in high LD (r^ = 0.83) had a similar OR of 0.74 (P = 0.006). In 
KCNJll, two significant SNPs (rs5219 and rs5215) had r^of 0.9 and with similar ORs of 
1.28 - 1.29 (0.024 <P < 0.025). In addition, three significant SNPs in HNF4A were in 
high LD (r^ > 0.69) and were all located in the P2 promoter region. Their effect sizes 
were similar with ORs ranged from 1.27 to 1.33 (0.007 < P < 0.021) for the risk C allele 
for rs4812828, T allele for rsl884614 and A allele for rs2144908. The high r^shared by 
the significant SNPs in these three genes suggested that only one signal is present for 
each gene. For the remaining genes showing significant association to T2D, rs881740 of 
PPARA showed the largest effect (OR = 1.59, P = 0.01), followed by rs 1472095 of 
PPARGCIA (OR = 1.52), rsl3239289 of GCK (OR = 1.48), rs2242062 of LIPC (OR = 
1.28) and rsl 169286 ofHNFlA ( 0 R = 1.23). 
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Stage 1 SNP Association to T2D 
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Figure 3.1 ： Graphical summary of association results for T2D for stage 1 SNPs in case 
control samples (shown as negative logio P value). The green line indicates the threshold 
of = 0.05. The SNP number corresponds to the SNP order shown in Appendix 2. 
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Table 3.2: Significant T2D association results of SNPs in stage 1 case-control 
samples 
SNP Gene rs n u m b e r M a j o r / M i n o r M A F M A F in OR (95% CI) P 
no. allele ^ in controls 
cases (N = 
(N = 290) 
467) 
"37 ADIPOQ *rs2241766 T/G oJTl 0.375 0.76 (0.62-0.94) 0 . 0 1 1 ^ 
39 ADIPOQ rsl063539 G/C 0.305 0.374 0.74 (0.6-0.92) 0.006 
49 PPARGCl A rs 1472095 C/T 0.069 0.103 0.66 (0.44-0.99) 0.042 
72 GCK rsl3239289 C/G 0.091 0.062 1.48 (1.0-2.19) 0.049 
86 KCNJll *rs5215 T/C 0.346 0.289 1.29(1.03-1.6) 0.024 
87 KCNJll *rs5219 C/T 0.347 0.29 1.28 (1.03-1.6) 0.025 
95 HNFIA rs 1169286 A/G 0.461 0.409 1.23 (1-1.51) 0.049 
105 LIPC rs2242062 A/G 0.375 0.317 1.28 (1.03-1.59) 0.024 
123 HNF4A rs4812828 C/T 0.454 0.526 0.75 (0.61-0.92) 0.007 
124 HNF4A *rsl884614 C/T 0.463 0.399 1.28 (1.05-1.57) 0.017 
125 HNF4A *rs2144908 G/A 0.469 0.406 1.27(1.04-1.56) 0.021 
146 PPARA rs881740 A/G 0.135 0.089 1.59 (1.12-2.25) 0.010 
Significant associations at P < 0.05 are bolded. 
* literature significant SNPs. 
a minor alleles were defined according to the frequencies in cases shown in Appendix 2. 
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3.2.2. Association with T2D subset by metabolic syndrome 
Metabolic syndrome (MetS) often coexists in T2D patients with insulin resistance, 
while T2D patients with primarily insulin deficiency are less likely to have multiple 
metabolic risk factors. To investigate the possible interacting effect of MetS and SNPs on 
T2D association, subset analyses which compared 223 MetS negative cases and 244 MetS 
positive cases to 290 controls respectively were performed. MetS was defined according 
to the NCEP criteria with central obesity definition modified for Asians (Section 2.2.3). 
The complete association results were shown in Figure 3.2 and Appendix 3. 
A total of 10 SNPs (6.6%) in 5 genes and 12 SNPs (7.9%) in 7 genes were 
significantly associated with MetS negative T2D and MetS positive T2D, respectively. 
Apart from the 10 (83%) T2D-associated SNPs (Table 3.2) that remained significant in the 
subset analyses, 10 additional SNPs demonstrated previously undetected associations. It 
is of interest to note that 4 genes {ADIPOQ, HNF4A, KCNJl 1 and LPL) had multiple 
association signals in the same MetS subgroup. Moreover, most SNPs were significant in 
only one subgroup except for rs291 of LPL and rs4812828 of HNF4A. 
In ADIPOQ, five SNPs in two LD blocks were significantly associated with MetS 
positive T2D. In LD block 2 (Appendix 1: Figure A 1.3), two closely associated SNPs 
(rs2241766 and rs 1063539) that showed previous association in overall T2D, as well as an 
additional SNP rs6773957 (r^ = 0.3 with rs2241766 and rsl063539) were significant (OR 
=1 .32 - 1.43, 0.005 < P < 0.027). In addition, two SNPs in LD block 1 (rs266729 and 
rs 182052, r^ = 0.5) showed independent association to MetS positive T2D (OR = 1.35 -
1.36, 0.018 < P < 0.036). 
In HNF4A, the three significant SNPs for overall T2D (rs4812828, rsl884614 and 
rs2144908) located in the P2 promoter regions of LD block 1 were more significant in the 
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MetS negative T2D subset (OR = 1.32 - 1.35, 0.016 < P < 0.027) than in the MetS 
positive subset (OR = 1.22 - 1.32, 0.021 <P < 0.089). In addition, an independent SNP 
located in LD block 2 (Appendix 1: Figure A 1.10), rs2071199, was also associated with 
MetS negative T2D subset with a similar effect size (OR = 1.43, P = 0.031). 
In KCNJJl, the two associated SNPs (rs5215 and rs5219) are in strong LD (r^ = 
1), with stronger association in the MetS positive T2D subgroup (OR = 1.34 - 1.35, 0.023 
<P< 0.026) than the MetS negative T2D subgroup (OR = 1 .23 - 1.24, P > 0.05). 
In LPL, none of the SNPs showed association with overall T2D but three SNPs 
were significantly associated with MetS negative T2D. This finding is due to the 
paradoxical opposite associations in the MetS subset analyses. While the C allele of rs291, 
G allele of rs320 and T allele ofrs4921684 increased risk for MetS negative T2D (OR = 
1.37 - 1.70，0.01 \ < P < 0.036), the former two risk alleles conferred trend of decreased 
risk for MetS positive T2D (OR = 1.37 - 1.70, 0.011 <P< 0.036). 
For the other genes with single association signals, SNPs in PBXl and PPARA 
showed suggestive association to MetS negative T2D，whereas SNPs in PPARG and 
UPC showed suggestive association to MetS positive T2D. Two SNPs in PPARGCIA 
showed trend of associations in different MetS subgroups, making the result inconclusive. 
In summary, additional loci and independent signals were observed in MetS 
subset analyses that were not detected in the overall case-control comparison. This is in 
part due to a stronger genetic effect when phenotypic homogeneity of sample was 
increased. In particular, the clustering of association signals in ADIPOQ in MetS positive 
T2D and HNF4A in MetS negative T2D were consistent with their expected roles in 
insulin action and insulin secretion, respectively. The association of PPARG and UPC 
with MetS positive T2D, and PBXl with MetS negative T2D were also consistent with 
5 6 
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their roles in the respective pathways. However, the association results for PPARGCIA, 
KCNJl I and PPARA did not entirely fit the pathways discussed in the hypothesis and 
warrant further investigation. 
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Figure 3.2: Graphical summaries of association results for stage 1 SNPs (shown as 
negative logio P value) in A) T2D without metabolic syndrome versus all controls; B) 
T2D with metabolic syndrome versus all controls. The green line indicates the threshold 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.3. Case-control associations in stage 2 
3.3.1. SNP selection for genotyping 
From the stage 1 association analyses on 1) all T2D cases vs. controls, 2) MetS 
negative T2D cases vs. controls, and 3) MetS positive T2D cases vs. controls, 22 SNPs in 
12 genes, except those in PDXl and NEURODl, showed nominal significance in one or 
more analyses. These SNPs were prioritized for genotyping in an independent stage 2 
samples consisted of 994 random T2D patients and 310 control subjects. Due to the 
strong LD between rs5215 and rs5219 of KCNJll (r^ 二 0.9)，only rs5219 was genotyped 
in stage 2. In addition, two literature significant SNPs (rs745975 of HNF4A and 
rs4148643 of ABCC8) were also included to refine the association signals within the large 
LD blocks in the respective genes. After removal of rsl 82052 in ADIPOQ that failed for 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.3.2. Association with T2D 
Figure 3.3 and Appendix 5 summarized the stage 2 association results of 22 
SNPs in 994 cases and 310 controls. None of the significant SNPs in stage 1 remained 
significant in stage 2. Despite the rare SNP rs2972164 of PPARG demonstrated a 
trend of association (尸=0.067)，the direction of association was opposite to that in 
stage 1 [OR (95 CI) 0.67 (0.44 1.01) in stage 1 vs. 1.5 (0.97-2.31) in stage 2]. 
Stage 2 SNP Association to T2D 
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Figure 3.3: Graphical summary of association results for T2D for stage 2 SNPs in 
case-control samples (shown as negative logio P value). The green line indicates the 
threshold of P = 0.05. The SNP number corresponds to the SNP order shown in 
Appendix 5. 
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3.3.3. Association with T2D subset by metabolic syndrome 
Subsequent subset analyses compared the genotype frequencies of 417 MetS 
negative cases and 578 MetS positive cases to 310 controls respectively. Figure 3.4 and 
Appendix 6 summarized the association results of two subset analyses in stage 2. Similar 
to the findings in the overall case-control comparison, none of the 22 SNPs remained 
significant in the subset analyses. However, the minor G allele of rs6773957 of ADIPOQ 
showed trend of increased association with MetS positive T2D, similar to that found in 
stage 1 [OR (95%CI) = 1.32 (1.03-1.69) in stage 1 vs. 1.20 (0.98-1.46) in stage 2]. 
The non-replication of association in overall and subset analyses between stages 1 
and 2 can be attributed to one or more of the following reasons: 1) different ascertainment 
criteria in which the stage 1 cases were likely to have stronger genetic effect than stage 2 
cases due to their younger age at diagnosis and higher degree of family history for 
diabetes; 2) overestimation of effect sizes in stage 1 and/or insufficient power in stage 2; 
3) type 1 error in stage 1 since multiple comparisons were not corrected. 
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Figure 3.4: Graphical summaries of association results for stage 2 SNPs (shown as 
negative logio P value) in A) T2D without metabolic syndrome versus all controls; 
B) T2D with metabolic syndrome versus all controls. The green line indicates the 
threshold of P = 0.05. The SNP number corresponds to the SNP order shown in 
Appendix 6. 
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3.4. Case-control associations in combined stages 1 and 2 
3.4.1. Association with T2D 
To further investigate the role of these SNPs in T2D susceptibility, samples in 
stages 1 and 2 were combined. This enlarged sample set with sufficient power allowed 
the examination of the best-fit genetic models and association with haplotype. Moreover, 
additional subset analyses will help to understand the confounding effects of MetS, age at 
diagnosis and gender on the genetic associations with T2D. Lastly, interaction and joint 
effects amongst SNPs could be examined to unravel the complex interplay of genes in 
different pathways on T2D. 
The genotype frequencies of 22 SNPs studied in both stages 1 and 2 were 
compared between 1462 cases and 600 controls (Table 3.5). In total, 4 SNPs in ADIPOQ, 
HNF4A and LPL were significant {P < 0.05), the former two genes were consistent with 
the results in stage 1 (Appendix 3). 
In ADIPOQ, two SNPs (rs6773957 and rsl063539) were significant in the 
additive model. The effect size of rs6773957 in the combined cohort (OR = 1.16, P = 
0.033) was similar to that of stage 1 (OR = 1.18, P = 0.112) and stage 2 (OR = 1.09，P = 
0.366). Rsl063539, which was in weak LD (r^ = 0.29) with rs6773957, also had similar 
ORs in stage 1 (0.74) and stage 1+2 (0.86). 
In HNF4A, rsl884614 was significant in both the additive (OR = 1.15，P = 0.049) 
and dominant (OR = 1.24, P = 0.038) models, similar to that found in stage 1 (OR = 1.28， 
P = 0.017). Furthermore, an independent SNP (rs745975) also showed a trend of 
association with T2D (OR = 0.84, P = 0.075). 
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111 LPL, rs320 was associated with T2D only in the recessive model (OR = 1.63, P 
=0.044) with the rare GG genotype (0.061 in cases vs. 0.040 in controls) being at risk. 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
Haplotype analysis was also performed to examine the association signals in 
ADIPOQ, HNF4A and LPL. The frequency of the CGAC haplotype of ADIPOQ was 
significantly lower in the cases than in the controls {P = 0.019) (Table 3.6). The 
protection effect of this haplotype was mainly driven by the protective G allele of 
rs2241766 and C allele ofrsl063539, which had r^  of 0.83. Similarly, the common at 
risk CTATG haplotype of HNF4A {F = 0.049) was mainly driven by the at risk T 
allele of rsl884614 and A allele of rs2144908 which were in strong LD (r^ = 0.94). 
No association was observed for LPL haplotypes. It is likely that single association 
signals in these genes contributed to T2D susceptibility. 
Table 3.6: Haplotype association of significant genes in stage 1+2 case-control samples 
Gene SNPs Haplotype Frequency P value 
Case Control 
(N= 1461) (N = 600) 
ADIPOQ *rs266729, G T ^ 0.151 0.339 
*rs2241766, CTGG 0.283 0.261 0.165 
rs6773957, GTAG 0.087 0.081 0.563 
rsl 063539 CGAC 0.280 0.318 0.019 
CTAG 0.190 0.863 
LPL rs291, "CCT 0096 o ! ^ 
*rs320, CGC 0.127 0.142 0.204 
rs4921684 TTC 0.777 0.775 0.889 
HNF4A rs4812828, CTATA oWa 
*rs 1884614, TCGTA 0.089 0.109 0.064 
*rs2144908, TCGCG 0.101 0.102 0.876 
rs2071199, CTATG 0.354 0.32 0.049 
*rs745975 TCGTG 0.322 0.333 0.506 
CCGTG 0.060 0.058 0.761 
Significant associations at P < 0.05 are bolded. 
* literature significant SNPs. 
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3.4.2. Association with T2D subset by metabolic syndrome 
Given the demonstrated value of combined analysis and increased phenotypic 
homogeneity, additional subgroup analyses involving 1) MetS; 2) age at diagnosis; 
and 3) gender were examined in the combined stages 1 and 2 samples in the following 
sections. 
From Table 3.7, 822 MetS negative cases and 640 MetS positive cases were 
compared to 600 controls respectively. Three SNPs (rs6773957 and rsl063539 in 
ADIPOQ and rs881740 in PPARA) were significant in the MetS positive subgroup 
comparison, while two SNPs (rs 1884614 in HNF4A) and (rs4921684 in LPL) were 
significant in the MetS negative subgroup comparison. 
In the comparison of MetS positive cases and all controls, the at-risk G allele 
of rs6773957 in ADIPOQ were consistently associated with T2D in stage 1 (OR = 
1.32, P = 0.027)，stage 2 (OR = 1.20, P = 0.079), and stage 1+2 (OR = 1.29，P = 
0.001). Rs 1063539 displayed a similar trend with its protective C allele. Even 
though the associations of rs266729 (P = 0.11) and rs2241766 (P = 0.07) did not 
achieve statistical significance, their at-risk alleles consistently trended towards 
association with the MetS positive T2D phenotype. In addition, rs881740 of PPARA, 
a gene upstream of ADIPOQ in the insulin action pathway, was also associated with 
MetS positive T2D with a modest OR of 1.29 {P = 0.036). However, this SNP showed 
stronger association with MetS negative T2D in stage 1，in contrast to the combined 
analyses. 
In the MetS negative subgroup analysis, the at-risk T allele of rsl884614 in 
HNF4A was consistent throughout the three stages, with ORs of 1.35 in stage 1, 1.09 
in stage 2 and 1.20 in stage 1+2. A similar trend of association was also observed for 
71 
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MetS negative T2D for an adjacent SNP (rs2144908) in strong LD (r^ = 0.94). For 
LPL, the at-risk T allele of rs4921684 also showed consistent trend of association 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.4.3. Association with T2D subset by age at diagnosis 
Familial diabetes usually occurs at a young age due to increased genetic loading. 
To investigate for a possible modifying effect of age of onset on diabetes, subset analyses 
comparing 759 early onset cases (age at diagnosis < 40 years) and 689 late onset cases to 
600 controls were performed respectively (Table 3.8). 
Three SNPs (rs2241766, rs6773957 and rsl063539) in ADIPOQ were 
significantly associated with late onset T2D (OR = 1.20 - 1.32, 0.001 <P < 0.046). On 
the other hand, SNPs from LPL (rs4921684) and PPARA (rs881740) were associated with 
early onset 丁2D (OR = 1.29 - 1.35，0.032 <P< 0.034). Moreover, two SNPs in HNF4A 
(rs 1884614 and rs745975) also showed a trend for association with early onset T2D, 
despite the former SNP may also be associated with late onset T2D {P < 0.1). 
Interestingly, the associated SNPs in ADIPOQ for late onset T2D coincided with 
that of MetS positive T2D, whereas the associated SNPs in HNF4A and LPL for early 
onset T2D coincided with that of MetS negative T2D, suggesting a possible correlation 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.4.4. Association with T2D subset by gender 
In view of a slightly higher female predominance of diabetes as well as sexual 
differences in phenotypes (e.g. lipids, body composition) and other environmental risk 
factors, subset analyses for T2D association were performed in men and women 
separately (Table 3.9). By comparing the genotype frequencies of 592 male cases with 
272 male controls, rs4921684 of LPL and rs4148643 of ABCC8 demonstrated 
nominal significant association with T2D (OR = 1.49 - 1.51, 0.028 <P < 0.044). On 
the other hand, rs6773957 of ADIPOQ showed significant association (OR = 1.23, P 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.4.5. Genetic epistasis for T2D association 
We observed consistent significant association of 5 independent SNPs (rs6773957 
and rs 1063539 of ADIPOQ, rsl884614 of HNF4A, rs4921684 of LPL, and rs881740 of 
PPARA) in one or more of the stage 1 and 2 analyses for overall T2D and subsets by 
MetS and age at diagnosis (Tables 3.5, 3.7 and 3.8). In order to test for possible 
interaction effect amongst these five SNPs on T2D association, a logistic regression 
model including the main effects of the five SNPs was built under an additive model. 
Then each of the possible two SNPs interaction was entered in a logistic regression model 
to test for significance of interaction, but none of the interactions were significant {P > 
0.05). 
In view of the heterogeneous nature of T2D and the different contribution of 
genes in specific pathways on different subtypes of diabetes, we hypothesized that 1) 
combination of genetic effects from genes in the same pathway may have stronger effect 
than that of a single gene in predisposition to T2D related to that pathway; 2) the 
coexistence of at risk genes from multiple pathways (insulin secretion and action in this 
study) may further increase the genetic predisposition to T2D. 
To test these hypotheses, the five SNPs were divided into two groups according to 
their association with MetS. As MetS often coexists with insulin resistance, three SNPs in 
ADIPOQ and PPARA that showed significant association with MetS positive T2D were 
considered related to the insulin action pathway. Conversely, two SNPs in HNF4A and 
LPL that showed significant association with MetS negative T2D were considered related 
to the insulin secretion pathway (Table 3.7). For each and the combined pathways, the 
number of at risk alleles carried by each subject was counted. For the 5 T2D-associated 
8 0 
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SNPs, each subject was classified into a low risk (0-2 risk alleles), medium risk (3 risk 
alleles), moderately high risk (4 risk alleles), or high risk allele (5-8 risk alleles) group 
according to the number of risk alleles carried. The 3 insulin action SNPs were similarly 
classified (0-1 risk alleles for low risk, 2 risk alleles for medium risk, 3 risk alleles for 
moderately high risk, and 4-6 risk alleles for high risk). The 2 insulin secretion SNPs had 
fewer risk alleles, so carriers with 0, 1, or 2-4 risk alleles were assigned to the low, 
medium, and high risk groups respectively. 
In view of the tendency of clustering of SNP association in MetS positive and 
late-onset T2D，as well as MetS negative and early-onset T2D，1182 diabetic subjects 
with complete genotypes for the five SNPs were classified into four groups to increase 
phenotypic homogeneity: 1) 331 MetS negative and early-onset T2D; 2) 188 MetS 
negative and late-onset T2D; 3) 315 MetS positive and early-onset T2D; 4) 348 MetS 
positive and late-onset T2D. Each of the diabetic subgroup was then compared with all 
controls according to the pathways involved. 
The results of the joint effects of the 5 SNPs for T2D association in different 
conditions were summarized in Table 3.10. For the three insulin action SNPs in 
ADIPOQ and PPARA, stronger association with risk for MetS positive late-onset T2D 
was observed in carriers with increasing number of risk alleles compared to low risk 
carriers (OR = 1.44 - 2.24, P for trend = 0.00008). Similarly, the two insulin secretion 
SNPs in HNF4A and LPL were strongly associated with MetS negative early onset T2D 
in a dosage-dependent manner (OR = 1.41 - 1.71, P for trend = 0.005). When combining 
SNPs from insulin secretion and action pathways, the association with MetS positive late-
onset T2D remained similar (OR = 1.44 - 2.24 for insulin action SNPs vs. OR = 1.66 -
81 
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2.08 for five associated SNPs), but the trend became insignificant for the MetS negative 
early-onset T2D (OR = 1.41 - 1.71 for insulin secretion SNPs vs. OR 二 1.22 - 1.62 for all 
five associated SNPs). When we combined all cases and compared them to controls, the 
effect sizes of the insulin action and insulin secretion SNPs were similar (OR = 1.33 -
1.49 for insulin action SNPs and OR = 1.26 — 1.43 for insulin secretion SNPs), and 
combining all five SNPs led to a stronger trend of association (OR = 1.43 - 1.65). The 
increased effect size by combining risk alleles and dividing patients into subgroups 
confirmed previous subset results and suggested the importance of dosage and 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3. Results 
3.5. Metabolic trait associations in control subjects in combined stages 1 and 2 
studies 
To investigate the effect of the 22 SNPs on metabolic risk factors, lineal-
regression was performed on 9 metabolic traits associated with: 1) lipid (HDL and 
TG); 2) blood pressure (SBP and DBP); 3) obesity (WHR); 4) insulin sensitivity 
(HOMA-IR and ISI); and 5) insulin secretion (HOMA-P and IDI) in 600 control 
subjects (Figure 3.5). Table 3.11 summarized the significant association of SNPs 
with quantitative traits. Among the nine traits tested, six genes {LPL, HNF4A, 
PPARA, PPARGCIA, ADIPOQ and LIPC) demonstrated significant associations to 
five traits related to lipids, insulin sensitivity and insulin secretion (P < 0.05). 
For LPL, the major T alleles of two SNPs (rs320 and rs291) in strong LD (r^ = 
0.95) were associated with decreased HDL level (0.002 < P < 0.003), insulin 
sensitivity (ISI) (P = 0.026), and insulin secretion (IDI) (0.022 < P < 0.044). While 
the association of this lipid gene with HDL level is expected, the association with 
insulin parameters is interesting. It is of note that five SNPs in other lipid genes 
{PPARA, PPARGCIA, ADIPOQ and LIPC) were also associated with insulin 
secretion including IDI and HOMA-p. Similarly，the major G allele of rs745975 in 
HNF4A was associated with both increased TG level and decreased insulin secretion 
(IDI). The association of multiple genes in regulation of both lipid levels and insulin 
secretion suggests that glucose and fatty acid metabolisms are interlinked and may be 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 4. Discussion 
CHAPTER 4. Discussion 
Type 2 diabetes (T2D) is a complex disease with a substantial genetic 
component. However, its pathophysiological mechanism is not fully understood. 
While the genome-wide approach is a hypothesis-generating tool to discover novel 
genes, a candidate gene association study is a hypothesis-testing tool to discern the 
genetic basis of complex diseases based on known molecular pathways. 
In this study, 14 candidate genes belonging to the insulin secretion or insulin 
action pathways were examined for association with type 2 diabetes in a Hong Kong 
Chinese population. The study was conducted in two stages. In stage 1, 152 SNPs 
were genotyped in 467 cases and 290 controls. A subset of 22 significant SNPs in 12 
genes were then genotyped in an independent cohort of 994 cases and 310 controls in 
stage 2 to balance genotyping cost and efficiency. As stated by Skol et al (Skol et al 
2006), combining the data from stages 1 and 2 will increase the power to detect an 
association. Thus we combined data from the two stages and further investigated the 
modifying effects of metabolic syndrome (MetS), age at diagnosis and gender, as well 
as gene-gene epistasis and joint effect on the susceptibility to T2D. While the 
combined sample size was sufficiently powered for detecting SNPs with a moderate 
effect size when using a nominal significance P value level of 0.05 (Section 2.1.2), 
the power after multiple comparisons (e.g. Bonferroni correction) was greatly 
diminished given the large number of SNPs tested. To minimize type 1 error while 
maintaining good study power, we declared significance by reproducible findings in 
different analyses. 
Among the 14 investigated genes, four (HNF4A, PPARA, LPL and ADIPOQ) 
demonstrated consistent strong associations with subtypes of T2D. While HNF4A is 
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a transcription factor (Noland et al.) regulating glucose stimulated insulin secretion 
(GSIS), PPARA, LPL and ADIPOQ are linked to adipocytes and play roles in lipid 
metabolism and insulin action pathway. Interestingly, these four genes seem to have 
dual regulatory roles in maintaining glucose and lipid metabolisms and thus enable 
cross-talk between the insulin secretion and action pathways. The key findings of this 
study are summarized in the following sections. 
4.1. Role of insulin secretion genes in type 2 diabetes 
Insulin is a key hormone for maintaining glucose homeostasis, thus defective 
insulin secretion is an important pathological mechanism for manifestation of T2D. 
Thus far, 6 genes have been identified to cause maturity-onset diabetes of the young 
(Yang et al), a monogenic form that accounts for 2-5% of diabetes (Fajans et al. 
2001). Remarkably, all these genes are primarily involved with the secretion (or the 
regulation) of insulin in the pancreatic P cells. This study examined the common 
polymorphisms of five of these genes {HNF4A, HNFIA, GCK, PBXl/PDXl and 
NEURODl), in addition to ABCC8 and KCNJll which are implicated in neonatal 
diabetes, for association with the more common form of T2D. 
HNF4A 
Hepatic nuclear factor 4a (HNF4a) primarily regulates gene expressions in 
the pancreatic p cells and the liver. In the p cells, it is the master regulator that 
initiates GSIS. In the liver, it responds to insulin stimulation by forming a regulatory 
network with other TFs (such as HNFla, PPARGClot, HNFip and F0XA2) to 
control hepatic gene expressions, leading to inhibition of hepatic glucose output and 
increased glucose uptake. 
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In the combined samples consisting of 1462 cases and 600 controls, the T 
allele of rs 1884614 was significantly associated with increased risk for overall T2D 
(OR = 1.15), and with stronger effect in the diabetic subgroup without MetS (OR = 
1.20) (Tables 3.5 and 3.7). Two SNPs (rs4812828 and rs2144908) with r^  > 0.71 to 
rsl 884614 also showed trend of association {P < 0.2) with both overall T2D and MetS 
negative T2D. In addition, the common G allele of rs745975 (r^ 二 0 to the three SNPs 
above) also conferred trend of increased risk to overall (OR = 1.19), MetS negative 
(OR 二 1.22) and early-onset T2D (OR = 1.23) {P < 0.1), further supporting its effect 
on T2D susceptibility. Interestingly, the G allele of rs745975 also demonstrated 
lower insulin secretion capacity (IDI) and higher TG level in healthy controls. 
Rsl884614, rs4812828 and rs2144908 are located at the P2 promoter region of 
HNF4A. Consistent with our results, the T allele of rsl884614 and other surrogate 
markers or haplotypes have been repeatedly shown to increase risk for T2D (OR = 
1.14 to 1.3) in multiple populations including Japanese, Europeans, Amish and 
Ashkenazi Jewish (Damcott et al. 2004; Hara et al. 2006; Johansson et al. 2007; 
Lehman et al. 2007), although negative findings were also reported (Vaxillaire et al 
2005; Winckler et al. 2005). Moreover, rs2144908 was associated with an earlier age 
of diagnosis of diabetes in Mexican American (Lehman et al. 2007). Despite a similar 
effect size observed across different ethnic groups, the T allele frequency of 
rsl884614 in Asians (0.40 - 0.45，this study and Hara, Horikoshi et al 2006) is 
different from that of Caucasians (0.2 - 0.27) and Pima Indians (0.83), suggesting 
stronger contribution of this gene region on T2D susceptibility in native Americans 
and Asians than in Europeans. 
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Another potential T2D-associated SNP, rs745975, is located 2 bp downstream 
from a consensus 3' splice site in intron 2. Contrary to a Japanese study with the A 
allele being at risk (Yokoi et al. 2006), the G allele showed trend of increased risk for 
T2D in this study. Nevertheless, a haplotype containing the G allele of rs745975 is 
associated with elevated TG level in Mexican and Finnish samples (Weissglas-
Volkov et al. 2006), which is consistent with our findings. Given that the Mexican 
and Finnish samples consisted of individuals with familial combined hyperlipidemia 
(FCHL) or premature history of coronary heart disease, their early onset of disease 
and dyslipidemic family history corroborates with our observed association with early 
onset diabetes. The G allele was also associated with lower IDI level in the current 
study, implying that the risk-conferring effect may be mediated through impaired 
insulin secretion. 
Functionally, the P2 promoter region of HNF4a is important for its specific 
regulation of gene expression in pancreatic islets through binding by other TFs 
including H N F l a , HNFip and PDXl (Thomas et al. 2001). SNPs flanking the 
promoter region may also affect splicing (Weissglas-Volkov et al. 2006). Defective 
function or expression of HNF4a will likely affect insulin secretion from the 
pancreatic p cells, as supported by the association of rsl884614 and rs745975 with 
development of MetS negative T2D and decreased IDI level, respectively. The 
association between rs745975 and TG level was supported by the recent observation 
that TG in the islets can induce GSIS. Taken together, we observed association of 
HNF4A polymorphisms with risk to develop early onset T2D in the absence of MetS. 
This is consistent with the a priori hypothesis and the literature, providing empirical 
evidence that link HNF4a-indiiced insulin secretory defect to T2D. 
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KCNJl 1/ABCC8 
Two adjacent genes on chromosome 11 code for the islet ATP-sensitive 
potassium channel (Kir 6.2 subunit encoded by KCNJl 1, and sulfonylurea receptor 
subunit encoded by ABCC8). The T allele of rs5219 (E23K) in KCNJl 1 has been 
widely replicated to confer risk for developing T2D in European populations (Nielsen 
et al. 2003; van Dam et al. 2005; Saxena et al 2007; The Wellcome Trust Case 
Control Consortium 2007; Zeggini et al. 2007) with an OR of � 1 . 1 4 . The T allele is 
also associated with decreased serum insulin level during OGTT (Nielsen et al. 2003)， 
suggesting that this effect is mediated through impairment of GSIS. Although this 
SNP did not reach statistical significance in this study, similar ORs of 1.07 — 1.13 
were observed in the overall T2D and MetS subset analyses of combined stages 1 and 
2 samples. The non-replication of rs5219 with T2D in Hong Kong Chinese may be 
due to insufficient power and thus a further large scale study in Chinese is warranted. 
Rs4148643 (also called rsl799859, R1273R and K649K) of ABCC8 is located 
in the same LD block (D' > 0.8) but has low r^  (0.02) with rs5219. The A allele was 
reported to be associated with a 2 fold increased risk for T2D in 490 Finnish with 
impaired glucose tolerance (Laukkanen et al 2004). However, the G allele was at-
risk for T2D in men in this study (OR = 0.67, P = 0.044). The inconsistency of 
direction of association and low minor allele frequency in Chinese (0.075 in controls) 
suggests that this SNP is less likely a genuinely associated SNP, although ethnic 
differences in the susceptibility allele could not be excluded. 
Other insulin secretion genes 
Although 6 genes belonging to the insulin secretion pathway demonstrated 
some evidence of association with T2D in stage 1，SNPs in 5 genes {PBXI, GCK, 
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KCNJll, ABCC8 and HNFIA) did not maintain their significance in the combined 
samples including 1462 cases and 600 controls for both overall T2D and subset 
analyses. In the combined stage 1+2，their ORs were modest (1.09 - 1.12 in the 
additive model, P > 0.05), with conflicting direction of association as compared to 
stage 1 and stage 2 respectively. This could be due to insufficient study power and/or 
type I error. 
Among these SNPs, rsl 169286 of HNFIA may warrant further investigation. 
The G allele showed some trend for increased risk for overall T2D in the combined 
samples (OR =1 .12 and 1.22 for additive and dominant models, respectively, P < 0.1). 
Similar to the pattern of association for rsl884614 of HNF4A, the G allele of 
rsl 169286 also showed trend for association with MetS negative T2D (OR = 1.15，户 
二 0.085) and early-onset T2D (OR = 1.14, P = 0.10) (Tables 3.7 and 3.8). Given that 
H N F l a and HNF4(x physically and functionally interact to regulate the expression of 
downstream genes, it is reasonable to speculate that their genetic variants would 
modulate similar disease phenotypes. 
The consistent association of polymorphisms at HNF4A with T2D 
susceptibility suggests that TFs that act as master regulators of genes for insulin 
secretion play a key role in T2D development. This observation is supported by the 
recent GWAS, which identified several T2D genes including TCF7L2 and HHEX, 
which are TFs regulating insulin secretion (Grant et al. 2006; Saxena et al 2007; 
Scott et al. 2007; Sladek et al 2007; Zeggini et al 2007). 
9 2 
CHAPTER 4. Discussion 
4.2. Role of insulin action genes in type 2 diabetes 
Under normal circumstances, insulin activates tissue-specific protein cascades, 
inducing liver to convert excess glucose into glycogen and triglyceride (Wittrup et al), 
as well as adipose tissue and muscle to store free fatty acids (FFA) as TG. However, 
the presence of insulin resistance leads to decreased insulin response of these target 
tissues, so that muscle and adipose reduce glucose and FFA uptake, while the liver 
outputs glucose instead of storing it. These effects disrupt the normal fat partition in 
the body and leads to elevated plasma glucose. In addition, while elevated glucose 
induces insulin secretion which controls FFA oxidation in the peripheral tissues, FFA 
also feeds back to the pancreas to release insulin to control plasma glucose level. 
Thus the insulin secretion and insulin action pathways interact closely to maintain 
energy homeostasis. Genetic defects that disrupt this regulatory network may lead to 
pathogenic consequences such as development of MetS and T2D. 
Among others, 6 genes {PPARG, PPARA, PPARGCIA, ADIPOQ, LPL and 
UPC) have been implicated in the control of lipid metabolism. PPARy regulates FFA 
uptake in adipose, while PPARa regulates FFA oxidation in the muscle and the liver. 
In the liver, lipases such as LPL and LIPC are responsible for removing TG from 
plasma lipids, and releasing FFA that can be easily absorbed by the cells. In the 
muscle, PPARGCla and ADIPOQ promote FFA oxidation to provide energy for 
activity. 
PPARA 
PPARA encodes the TF peroxisome proliferator-activated receptor-a, a key 
regulator of ADIPOQ and LPL activities that are involved in the FFA oxidation in the 
liver and muscle. Similar to PPARy, PPARa is a drug target for lowering TG and 
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cholesterol in hyperlipidemic patients, as well as improving insulin sensitivity and 
GSIS in diabetic patients. 
In the combined stages 1 and 2 analyses, the G allele of rs881740 was 
modestly associated with MetS positive T2D (OR = 1.28，P = 0.036), as well as early-
onset T2D (OR = 1.29, P = 0.034) (Tables 3.7 and 3.8). Rs881740 is a novel T2D-
associated SNP discovered through the tagging approach. The association of this 
SNP with MetS in the diabetic patients is consistent with the regulatory role of 
PPARa in both glucose and lipid metabolisms, which are often disrupted in patients 
with MetS. In animal studies, PPARa-null mice demonstrated decreased hepatic 
glucose production during fasting as compared to the wildtype mice (Patsouris et al 
2004). In addition, these null mice also accumulated lipids in the heart and liver when 
FFA influx was inhibited (Djouadi et al 1998). Our finding of an association with 
early-onset T2D was also supported by a recent study which found association of a 
PPARA haplotype with 3.75-fold increased risk of developing early onset T2D before 
the age of 45 years old (Flavell et al 2005). 
ADIPOQ 
ADIPOQ encodes the hormone adiponectin which is exclusively expressed in 
the adipocytes that regulates energy homeostasis. As a major insulin-sensitizing 
cytokine, adiponectin stimulates fat storage in the adipose tissue, inhibits glucose 
output in the liver and provides TG as an energy fuel in the muscle. 
In the combined stages 1 and 2 analyses, two independent SNPs of ADIPOQ 
(rs6773957 and rsl063539) were significantly associated with T2D, especially the 
forms with MetS positive (OR = 1.19-1.29) and late-onset T2D (OR = 1.30-1.33), as 
well as for diabetes in women (OR = 1.2-1.23). In addition, the T allele ofrs2241766 
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(r^ = 0.83 with rsl063539) also showed a trend for increased risk for T2D in the 
subgroup analyses. The moderately increased ORs in the subgroups, as compared to 
the whole group, indicate that increased phenotypic (and thereby genetic) 
homogeneity may help to clarify the specific effects of the SNPs. Interestingly, the 
T2D risk alleles of rs2241766 and rs6773957 were also associated with lower 
HOMA-p index, suggesting that adiponectin may also play a role in maintaining 
homeostasis in p-cell insulin secretion. 
Rs6773957, rsl063539 and rs2241766 are all located in LD block 2. 
Rs2241766 is a synonymous coding SNP located in exon 2, whereas rs6773957 and 
rsl063539 are located in the 3' untranslated region near exon 3. SNPs in this LD 
block have been previously reported to be associated with T2D (Hara et al. 2002; 
Menzaghi et al. 2002; Yang et al. 2007), although negative findings were also 
reported (Gibson et al 2004; Gu et al 2004; Lee et al 2005). Consistent with our 
findings, the T allele of rs2241766 confered risk for MetS related phenotypes 
(especially obesity) in an Italian population (Menzaghi et al. 2002)，and was further 
associated with insulin resistance and cardiovascular diseases in a subsequent meta-
analysis in Caucasians (Menzaghi et al. 2007). In a healthy Austrian population, this 
allele is also associated with lower serum adiponectin level (Mackevics et al. 2006), a 
predisposition to T2D development. However, a meta-analysis involving 2379 
Chinese subjects suggested that the G allele was at risk for T2D (P = 0.05) (Li et al. 
2007). 
In this study, it is unclear why SNPs in the LD block 2 were associated with 
HOMA-p rather than with HOMA-IR which is closely linked to MetS. One possible 
mechanism is by indirect modulation of pancreatic P-cell function through regulation 
of FFA metabolism. On the other hand, the female-specific risk for T2D may be 
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partially explained by the known sexual variation in plasma adiponectin level 
(Kadowaki et al. 2006). In a study involving 1727 Caucasians, 18% of the variance 
of adiponectin concentration was explained by gender alone (Heid et al 2006). A 
Taiwanese study showed that girls have higher plasma adiponectin level than boys, 
and that adiponectin level was inversely correlated with plasma insulin level (Hung et 
al. 2006). Stumvoll et al. demonstrated that genetic association of ADIPOQ with 
insulin sensitivity was only found in the subgroup without first degree family history 
of diabetes (Stumvoll et al. 2002). Despite some conflicting results in ours and 
others' studies, which may be due to difference in ascertainment, ethnicity and/or type 
1 error, the data collectively suggest that polymorphisms in ADIPOQ may aggravate 
insulin resistance and/or impair GSIS in the presence of other risk factors such as 
aging and obesity. 
LPL 
LPL encodes the enzyme lipoprotein lipase that controls the rate-limiting step 
in the lipolysis of TG. In the adipose tissue, insulin stimulates LPL to convert plasma 
lipoproteins into FFA for cellular nutrient uptake, whereas in the muscle and liver, 
LPL releases FFA as an energy fuel when insulin is absent. It has also been suggested 
that LPL inversely controls insulin secretion through the long-chain acyl-CoA (Lc-
CoA) and the GPR40 signaling pathway in the pancreatic p cells，leading to enhanced 
insulin secretion in response to insulin resistance. Thus, LPL may play multiple roles 
in both glucose and fatty acid metabolisms. 
In the combined stages 1 and 2 analyses, the T allele of rs4921684 in LPL 
demonstrated significant association with MetS negative T2D (OR = 1.37), early-
onset T2D (OR = 1.35), and increased T2D risk in men (OR = 1.51). Given the 
known function of LPL in the regulation of lipid levels, its associations with MetS 
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negative and early-onset T2D seemed to be contradicting as both phenotypes may be 
more affiliated with defective insulin secretion (as observed in rsl884614 of HNF4A). 
Given that lipid traits are regulated by hormones such as insulin, glucagon and growth 
hormone that are subject to gender-specific variations, lipid-related genes may also 
exert gender effect. An earlier study has reported an association of Ser447X (in low 
r2 with rs4921684) with T2D in women (Larson et al. 1999). The at-risk effect of 
rs4921684 in men in this study is unclear, but it could be linked to indirect effects 
such as stress and other environmental factors. 
Apart from rs4921684, two correlated SNPs (rs320 and rs291) demonstrated 
nominal association with overall T2D (OR 二 1.54 — 1.63, P < 0.1) under a recessive 
model. Interestingly, these two SNPs were also associated with lipids (HDL), insulin 
sensitivity (ISI) and insulin secretion (IDI) in the control subjects. However, the T2D 
conferring G allele was associated with better metabolic profiles. Rs320 (also known 
as Hind[\l and T495G) is an intronic SNP that disrupts a Hindlll restriction enzyme 
recognition site by replacing thymine (T) with guanine (G). It has been repeatedly 
associated with hypertension (Chen et al. 2005; Yang et al 2005), atherosclerosis 
(McGladdery et al 2001) (Gotoda 1999) and cardiovascular diseases (Elosua et al 
2006) in several Caucasian and Chinese cohorts. However, few studies on T2D have 
been investigated, and the results are conflicting (Wang et al. 1996; Larson et al. 
1999). In a case-control hypertension study in Chinese (Ma et al. 2003), the G allele 
(H- allele) was associated with elevated HDL, consistent with the current findings. 
Taken together, the results of rs320 and rs4921684 suggest a role of LPL in 
the regulation of both glucose and lipid metabolisms. In a recent GWAS for blood 
lipids in 6650 healthy subjects, LPL was the only loci confirmed to be associated with 
TG and HDL levels (Kathiresan et al. 2007). Decreasing LPL's activity in mice has 
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led to elevated TG and reduced HDL. A clinical trial in Japanese found that patients 
with TG genotype (and not GG genotype) for rs320 had significantly reduced area 
under the curve of plasma glucose when treated with Simvastatin (Onai et al. 1999)， 
which suggests an effect on glucose metabolism. Indeed, LPL is regulated by 
glucose-induced insulin signaling cascade in the adipose tissues, while LPL releases 
FFA to inversely regulate insulin secretion in the islets. In animal study, acute 
exposure of FFA to rat islets increases GSIS, while chronic exposure insensitizes 
islet's response to glucose (Sako et al. 1990), perhaps due to lipotoxicity-induced p 
cell apoptosis (Lee et al. 1994). 
Other insulin action genes 
Although 6 genes belonging to the insulin action pathway reached statistical 
significance for association with T2D in stage 1, 4 SNPs in 3 genes {PPARG, 
PPARGCIA and LIPC) did not maintain their significance when 1462 cases were 
compared to 600 controls in the combined stages 1 and 2 (P > 0.05). These 4 SNPs 
had not been previously reported to be associated with T2D. It is possible that the 
apparent associations of rs 12650562 (in PPARGCIA) to IDI，and rs2242062 (in LIPC) 
to HOMA-P may reflect statistical fluctuations. A Pro 12 Ala (rs 1801282) 
polymorphism in PPARG has been widely replicated to be associated with T2D in 
Caucasians (Saxena et al. 2007). However, this SNP was not significant in the present 
stage 1 study and failed for genotyping in stage 2. A previous study in 2730 Chinese 
also observed inconsistent results (Tai et al. 2004). 
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4.3. Combined genetic effects on risk for type 2 diabetes 
Despite the absence of gene-gene interaction, a joint or additive effect was 
observed for the five associated SNPs (rs6773957 and rsl063539 of ADIPOQ, 
rsl884614 of HNF4A, rs4921684 of LPL, and rs881740 of PPARA). Due to the 
predominant effect of HNF4A and LPL on MetS positive and early-onset T2D, and 
the preferential effect of ADIPOQ and PPARA on MetS negative and late-onset T2D 
(Table 3.7), these two sets of genes were examined for association with different 
subtypes of T2D separately and jointly. 
The results in Table 3.10 demonstrated that insulin secretion SNPs (HNF4A 
and LPL) were only associated with MetS negative early-onset T2D (OR = 1.41 - 1.71, 
P for trend = 0.005) whereas insulin action SNPs {ADIPOQ and PPARA) were only 
associated with MetS positive late-onset T2D (OR = 1.44 - 2.24, P for trend = 
0.00008). The stronger effect size achieved by: 1) combining SNPs; 2) increasing 
number of risk alleles; and 3) the same direction of association in the joint SNP 
analyses (as compared to individual SNPs) confirm that these SNPs influence the 
susceptibility of different forms of T2D, in agreement with the heterogeneous nature 
of the disease. Moreover, in view that all five insulin secretion and action risk SNPs 
demonstrated increased effect size (OR = 1.43 - 1.65) as compared to SNPs in 
individual pathways (OR = 1.26 — 1.49) for overall T2D, possible detrimental 
synergistic effect of multiple risk alleles in multiple pathways exists for T2D 
development. These joint genetic effects were also observed in a recent Chinese study 
on seven diabetes genes discovered through GWAS (Ng et al. 2008). 
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4.4. Summary 
T2D is an emerging world epidemic, and it has particularly strong impact in 
China given its recent industrialization and the adaptation to an unhealthy lifestyle. 
Based on previous literature, this study hypothesizes that defects in transcription 
factors and their downstream target genes in the insulin secretion and action pathways 
may confer increased susceptibility for T2D. To investigate this hypothesis, 8 genes 
{HNF4A, HNFIA, KCNJII, ABCC8, GCK, NEURODl and PDXl) were selected 
from the insulin secretion pathway and 6 genes {PPARA, PPARG, PPARGCIA, 
ADIPOQ, LPL and LIPC) were selected from the insulin action pathway. Literature 
significant SNPs and tagSNPs that captured most of the common variations in each 
gene were genotyped in a subset of samples in stage 1，and interesting signals were 
followed up in a larger stage 2 cohort. The overall results suggest that these 4 genes 
play a subtle role in development of T2D and regulation of its related metabolic traits. 
The patterns of genetic associations 
In the current study, genetic variants in HNF4A, PPARA, ADIPOQ and LPL 
were associated with T2D in the Hong Kong Chinese population using multiple 
analytical methods. From the current knowledge, HNF4a belongs to the insulin 
secretion pathway, while PPARa, ADIPOQ and LPL belong to the insulin action 
pathway. As expected, genes in different pathways display different patterns of 
association, such as the association of HNF4A with MetS negative and early-onset 
T2D，and the association of ADIPOQ with MetS positive late-onset T2D. Conversely, 
the lack of association with metabolic traits in PPARA and the association of MetS 
negative early-onset T2D in LPL prompt additional investigations for their role in 
T2D development. 
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The role of transcription factors and adipocyte-secreted proteins in T2D 
The important roles of TFs and adipocyte-related proteins on T2D are 
highlighted in this study. TFs regulate the expression of a large set of target genes, 
and they act as genetic switches between metabolic pathways to coordinate 
appropriate changes in response to environmental stimulus. As hypothesized, two 
TFs {HNF4A and PPARA) were associated with early-onset T2D. HNF4a is a master 
regulator of the signaling cascade that induces GSIS. Other TFs such as TCF7L2 and 
HHEX are also implicated for T2D through action on GSIS (Grant et al. 2006; Sladek 
et al. 2007). It is unclear why other TFs were not associated with T2D in the current 
cohort, but larger studies are required to confirm or refute these negative findings. 
Adipose tissue is increasingly recognized for its role in controlling lipid and 
glucose metabolisms throughout the body (Rosen et al, 2006). Two of its secreted 
proteins, ADIPOQ and LPL, were associated with T2D in the present study. When 
fat cells are unsaturated, they release starvation signals (such as ADIPOQ) to promote 
glucose uptake in insulin target tissues. When fat cells are saturated, they release 
satisfaction signals to inhibit glucose uptake, and induce LPL to convert TG into FFA. 
These secreted proteins thus maintain the energy balance between glucose and FFA in 
the adipose tissue. The key role of adipocyte proteins in T2D is supported by the 
association of other adipocytokines (such as leptin and TNFa) and T2D. The 
presence of severe insulin resistance and glucose intolerance in adiponectin knock-out 
mice (Matsuzawa 2005) also support our observations. 
An integral pathway for T2D 
Extensive studies have implicated the role of insulin secretion genes in 
glucose metabolism, and insulin action genes in lipid metabolism. In the current 
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Study, however, the four T2D susceptibility genes were linked to both lipid and 
glucose metabolic traits irrespective of their pathways. For example, HNF4A was 
associated with TG level while lipogenic genes such as ADIPOQ and LPL were 
associated with insulin secretion index in control subjects. This paradoxical picture 
suggests that these candidate genes may control glucose and lipid metabolisms 
simultaneously in a complex regulatory network. 
Key findings of this study 
There are three key findings in the present study. Firstly, genetic variants in 
HNF4A, PPARA, LPL and ADIPOQ were associated with T2D in our Hong Kong 
Chinese population, suggesting the role of GSIS-related TFs and adipocyte-related 
proteins in the development of T2D. Secondly, the four associated genes were likely 
involved in the regulation of both glucose and lipid metabolisms, and through their 
dual regulatory roles achieved cross-talk between the insulin secretion and action 
pathways. Thirdly, joint effects of genes from one or multiple pathways greatly 
improved the predictive power for T2D, and supported the usefulness of an integrated 
approach in the genetic studies of complex diseases such as T2D. 
4.5. Limitation of this study and future direction 
The effect of power 
This study was designed to have sufficient power (> 80%) to capture common 
SNP association at a nominal type I error rate of 5% with odds ratios (ORs) ranging 
from 1.3 to 1.8 in the stage 1 samples, and ORs of 1.2 to 1.5 in the combined stages 1 
and 2 samples. Given that most T2D genes discovered in recent GWAS have very 
modest effect sizes (OR < 1.3) except for TCF7L2 (Zeggini et al 2007; Zeggini et al. 
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2008), our study may not have sufficient power to detect associations for rare SNPs 
and SNPS with smaller effects. Due to limited power, multiple comparison correction 
was not performed. By accepting a larger type 1 error rate, the data were interpreted 
with caution and guided by consistency across different analyses. 
The effect of genetic and phenotypic heterogeneity 
Inconsistent or non-replicated findings may be attributable to several reasons 
including ethnic differences in risk markers, alleles and/or frequencies, different study 
designs and over-estimation of effect size by first report (winner's curse). One 
method to overcome winner's curse is to increase sample size in the follow up studies. 
In the current study, we did not observe replication of stage 1 results using the stage 2 
samples, but some associations were observed in the combined analyses of stages 1 
and 2，in particular during the subset analyses. This can be partly explained by the 
sampling differences and phenotypic heterogeneity between stage 1 and stage 2. 
Unlike stage 1 cases with all early-onset diabetes, stage 2 cases were more 
heterogeneous with both early- and late-onset diabetes and with weaker family history 
of diabetes. This difference in genetic loading makes direct comparison of the two 
stages results difficult. On the other hand, combining samples in the two stages 
conferred greater power and supported subset analyses based on phenotypes. Indeed, 
the increased phenotypic (and thus genetic) homogeneity in the sub-phenotypic 
analyses revealed associations unobserved in the overall samples comparison. 
Together, these results highlighted the importance of using a homogeneous cohort to 
explore small genetic effects in complex diseases. 
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Future direction 
This study contributes to the current literature by identifying HNF4A, PPARA, 
ADIPOQ, and LPL as the T2D candidate genes in Hong Kong Chinese. The 
importance of transcription factors and adipocyte-related proteins in T2D 
development was highlighted. Further studies are warrant to understand the role of 
these genes. Firstly, these results should be validated by association studies in larger 
cohorts of Chinese or Asians. Prospective cohort studies will be particularly useful 
for the predictive role of these genes on T2D. Secondly, gene-gene interactions 
should be explored with other genes in the insulin secretion and action pathways. 
Thirdly, functional studies such as reporter assays and gene knock-out studies would 
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Appendix 1: Gene structure and linkage disequilibrium of genotyped SNPs of 
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Figure A1.1: PBXl. A) Gene structure; B) Analyzed SNPs; C) D，plot; D) r^  plot. 
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Figure A1.2: PPARG. A) Gene structure; B) Analyzed SNPs; C) D’ plot; D) r^  plot. 
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Figure A1.3: ADIPOQ. A) Gene structure; B) Analyzed SNPs; C) D' plot; D) r^  plot. 
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Figure A 1.4: PPARGCl A. A) Gene structure; B) Analyzed SNPs; C) D' plot; D) r^  
plot. 
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Figure A 1.6: LPL. A) Gene structure; B) Analyzed SNPs; C) D，plot; D) r^  plot. 
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Figure A1.7: KCNJl 1/ABCC8. A) Gene structure; B) Analyzed SNPs; C) D' plot; D) 
r^  plot. 
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Figure A 1.8: HNFIA. A) Gene structure; B) Analyzed SNPs; C) D，plot; D) r^  plot. 
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Figure A 1.9: LIPC. A) Gene structure; B) Analyzed SNPs; C) D，plot; D) r^  plot. 
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Figure Al.lO: HNF4A. A) Gene structure; B) Analyzed SNPs; C) D, plot; D) ？ plot. 
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It is the time I have spent on my rose that makes my rose so important. 
—Antoine de Saint- Exupery, Le Petit Prince 
• 
C U H K L i b r a r i e s 
• • 1 1 
0 0 4 5 6 1 3 1 1 
